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ABSTRACT
THE ROLE OF THE MIR-200 FAMILY ON THE TUMOR SUPPRESSOR RASSF2
AND THE EFFECT ON MAPK PATHWAY ACTIVITY IN COLORECTAL CANCER
Jane V. Carter
November 22nd 2016

This dissertation investigated the role of the miR-200 family in normal colon
epithelial (CCD 841) and Dukes’ C (HT-29) colorectal cancer (CRC) cell lines. Our aim
was to characterize expression of the miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141, and miR-429) in colorectal cell lines, study their effect on the tumor suppressor
Ras Associated Domain-Containing Protein (RASSF) 2 and on subsequent activity within
the mitogen-activated protein kinase (MAPK) signaling pathway. We wanted to
determine whether regulation of miR-200 family members could change cell behavior
towards more “cancer-like” in a normal colon epithelium (CCD 841) cell line, or less
“cancer-like” in a Dukes’ C (HT-29) CRC cell line.
We found the following:
1. All miR-200 family members were highly expressed in colorectal cancer cell lines
compared to a normal colon epithelial cell line.
vii

2. RASSF2 mRNA and protein expression was downregulated in all CRC cell lines
compared to the normal colon epithelial (CCD 841) cell line.
3. Overexpression of miR-200 family members in a normal colon epithelial (CCD
841) cell line decreased expression of both RASSF2 mRNA and protein.
4. Inhibition of miR-200 family members in a Dukes’ C (HT-29) CRC cell line
increased expression of both RASSF2 mRNA and protein.
5. Total K-Ras expression and phosphorylation of ERK 1/2 increased following
overexpression of miR-200 family members in a normal colon epithelial (CCD
841) cell line, indicating increased activity within the MAPK pathway resulting in
increased cell proliferation.
6. MAPK pathway activity decreased, as measured by reduced ERK 1/2
phosphorylation and reduced cell proliferation in a Dukes’ C (HT-29) CRC cell
line following inhibition of miR-200 family members.
These findings demonstrate a novel association of the miR-200 family, the tumor
suppressor RASSF2, and the MAPK signaling pathway in CRC. In contrast to the
previous understanding that miR-200 family dysregulation is considered to exhibit tumor
suppressive behavior by blocking epithelial to mesenchymal transition, we refute this in
the case of CRC and propose the miR-200 family contribute to CRC tumorigenesis. This
improved understanding of the miR-200 family may have the potential to be developed as
a therapeutic intervention in CRC.
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PREFACE

During my general surgical registrar training in the South West of England I was
fortunate to have the opportunity to conduct research at the Price Institute of Surgical
Research under the mentorship of Dr. Susan Galandiuk, Louisville, Kentucky.
I was introduced to a laboratory working with colorectal cancer cell lines and
microRNAs as biomarkers for the detection of colorectal cancer. It was here I became
interested in the differential expression of miRNAs between cancers that were locally
confined (surgically curable) and those that had begun to metastasize (less likely to be
cured by surgery). As a way of learning laboratory techniques and cell culture I
performed miRNA screening studies on four colorectal cancer cell lines, two locally
confined and two metastatic, and one normal colon epithelium, to determine whether
there were differences in miRNA expression. This resulted in the observation that the
miR-200 family members were highly expressed in colorectal cancer. Research into the
miR-200 family identified an association with the tumor suppressor RASSF2 and after
confirmatory studies, a hypothesis was generated.
Based upon the screening results and my thesis committee’s advice, a Dukes’ C
(HT-29) colorectal cancer cell line and a normal colon epithelial (CCD 841) cell line
were selected for further study. A commonly dysregulated pathway in colorectal cancer is
the MAPK signaling pathway. This pathway is a major regulator of cell proliferation.
xviii

For this reason we chose to study the effect of the miR-200 family on both proliferation
in the Dukes’ C (HT-29) colorectal cancer cell line and the normal colon epithelial (CCD
841) cell line.
Another goal was to perform gain and loss of function studies of the miR-200
family with the idea that colorectal cancer cells would adopt less malignant behavior,
whereas normal colon epithelial cells would have more malignant behavior.
I have enjoyed learning and understanding the processes involved in scientific
research and I have deepened my knowledge on aspects contributing to surgical disease.
This has set the foundations on which I will take back with me to the United Kingdom to
develop my own practice and begin my career in academic surgery.
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CHAPTER I
INTRODUCTION

a)

Epidemiology and Risk Factors for the Development of Colorectal Cancer
Colorectal cancer (CRC) is common worldwide and associated with significant

mortality. In the United States alone in 2015, CRC was the third most common cancer in
men and women with approximately 135,000 new cases diagnosed (Figure 1). It was also
accountable as the third most leading cause of cancer deaths continuing to make CRC an
enormous public health burden (Figure 2).(1) Most patients present with late stage
disease and the 5-year survival for patients with newly diagnosed colon cancer with
distant metastases is less than 15% (Figure 3).(2) Overall, the current lifetime risk of
developing CRC is approximately 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for
women.(2)
The underlying causes of CRC are complex and heterogeneous. Most sporadic
CRC develops from precursor polyps, namely advanced adenomas and
hyperplastic/serrated polyps. Adenocarcinomas form more than 95% of all colorectal
cancers. Other less common types of tumors to develop in the colon and rectum include
carcinoid tumors, gastrointestinal stromal tumors, lymphomas and sarcomas.

1

Figure 1. Estimated New Cases of Colorectal Cancer in the United States 2015

2
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

Figure 2. Estimated Colorectal Cancer Deaths in the United States 2015

3
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

Figure 3. Percent of Cases and 5-Year Relative Survival by Stage at Diagnosis for Colorectal Cancer

4
Sheets SSF. Colon and Rectum Cancer. Cancer Statistics: Statistical Summaries National Cancer Institute. 2014.
Available from: http://seercancergov/statfacts/html/colorecthtml [Accessed 28th September 2016].

Both environmental and inherited risk factors have also been identified to
contribute to the development of CRC. Modifiable environmental factors include a high
fat/high red meat diet, excess alcohol consumption, obesity, smoking, and lack of
physical activity. Non-modifiable risk factors such as an older age, a personal history of
colorectal polyps or inflammatory bowel disease, a family history of colorectal cancer in
a first-degree relative, or having an inherited syndrome can all contribute to the
development of CRC.
b)

Diagnosis of Colorectal Cancer
As stated, the majority of colorectal cancer present at a late stage. This is due, in

part, to a delay in presentation of symptoms and signs associated with CRC. In addition,
many of these general symptoms, such as abdominal discomfort, bloating, and irregular
bowel movements, are often caused by other conditions than cancer. “Red flag” signs
include rectal bleeding, blood within the stool, unintentional weight loss, fatigue and
unexplained iron-deficiency anemia.
Colonoscopy is the current “gold-standard” for screening and diagnosis of
colorectal neoplasia and has >95% sensitivity and 90% specificity.(3) It allows for
removal of precancerous polyps, and according to case-control and cohort studies,
decreases both CRC incidence and CRC related mortality.(4-8) Colonoscopy is; however,
expensive, invasive, has a risk of complications such as bowel perforation, and has a
relatively high rate of patient non-compliance. The screening interval of 10 years for
colonoscopy has a detection rate of early CRC of only 18-35%.(9-12) Despite these
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shortcomings, the broad use of colonoscopy for the last 3 years in the U.S. has been
associated with a significant decrease in frequency of CRC.(13)
Flexible sigmoidoscopy has been shown to decrease both CRC incidence as well
as the mortality of distal CRC.(14) Other “imaging” tests for cancer screening include
barium enema and virtual colonoscopy. Disadvantages of such screening include 1) high
patient non-compliance, 2) the invasive nature of such procedures, 3) the need for
sedation for colonoscopy, 4) rare patient morbidity such as colon perforation,(15) 5) the
need for vigorous bowel cleansing, and 6) expense.(16)
Available less-invasive tests include stool-based assays, such as the guaiac and
immunochemical fecal occult blood tests (FOBTs) and DNA-based tests.(17) Although
immunochemical FOBTs are superior to guaiac FOBTs, their ability to detect
premalignant colorectal adenomas is limited. A recent German prospective screening
study assessed the two best-performing immunohistochemical FOBTs and determined the
sensitivity for detection of advanced adenomas of 25% and 27%.(18) Stool-based DNA
testing identified 54% of patients with adenomas >1 cm in size with 90% specificity.(19)
Due to the nature of the tested substance, stool-based testing is not popular among
patients, physicians, or lab personnel. A stool-based bowel-screening program in the
United Kingdom found that only 50% participated in screening; and of those with an
abnormal guaiac FOBT, only 83% underwent subsequent colonoscopy.(20)
The only plasma-based assay that has been regularly available for clinical
monitoring, and, in some cases, for CRC screening, has been the carcinoembryonic
antigen (CEA) assay, which is also used for post-operative surveillance and for
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monitoring response to therapy. CEA lacks sufficient sensitivity and specificity (36-74%
and 87% respectively) for use as a population screening tool or for detecting CRC
recurrence.(21, 22) Carbohydrate antigen 19-9 (CA 19-9) has also been used as a
prognostic tumor marker, but it is even less sensitive than CEA for CRC.(23) Recently,
CA11-19, has been identified as a promising serologic tumor marker which has been
reported to detect early CRC with a sensitivity of 98% and specificity of 84%.(24)
c)

Colorectal Cancer Staging
Cancer staging is performed for diagnostic purposes and to also determine the

best treatment for patients. Staging in CRC refers to the extent of local invasion, the
degree of lymph node involvement, and whether there is distant metastasis. The most
common and accepted staging system from the American Join Committee on Cancer
(AJCC) is called the Tumor Node Metastases (TNM) system. This system is comprised
of three categories, where by “T” represents the degree of invasion of cancer into the
bowel wall, “N” the amount of lymph node involvement, and “M” to the presence of
metastasis (Figure 4) (Table 1). The older Dukes’ staging of colorectal cancer, described
by a British pathologist in the 1930’s and more commonly used within Europe, has
largely been replaced by the TNM staging system to ensure a standardized practice of
reporting. The initial Dukes’ classification was divided into three categories, Dukes’ A,
B, and C with each stage representing more advanced disease (Figure 5). Modifications
to the Dukes’ classification have been developed, such as the Astler-Coller classification,
which subdivided Dukes’ B and C stages, and added a D stage for metastatic disease, to
allow for more detailed information for the prognosis and management of the cancer.

7

Figure 4. Tumor Node Metastases (TNM) Staging of Colon Cancer

T

represents how far the primary tumor has grown into the intestinal wall and
whether it has invaded nearby surrounding tissues

N

denotes the number of regional lymph nodes infiltrated by disease

M

indicates if the cancer has metastasized to other organs of the body

Kasper D, Fauci A, Hauser S, Longo D, Jameson J. 2015. Harrison's Principles of
Internal Medicine. 19th ed. New York: McGraw-Hill Education.
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Table 1. Modified AJCC TNM Staging and Corresponding Dukes’ Classification

Primary
Tumor (T)

Regional
Lymph Nodes
(N)

Distant
Metastases
(M)

Dukes’ Stage

Primary
Tumor

0

Tis

N0

M0

-

Tis – Cancer in
situ

N0 – No regional
lymph nodes

I

T1/2

N0

M0

A

T1 – Invasion
into submucosa

N1 – Metastasis in
1-3 pericolic nodes

IIA

T3

N0

M0

T2 – Invasion
into muscularis
propria

N2 – Metastasis into
≥ 4 pericolic nodes

IIB

T4a

N0

M0

IIC

T4b

N0

M0

IIIA

T1/2

N1

M0

IIIB

T3/4

N1

M0

IIIC

Any T

N2

M0

IV

Any T

Any N

M1

9

Stage

B

Regional Lymph
Nodes

Distant
Metastasis
M0 – No
metastasis
M1 –
Distant
metastasis

T3 – Invasion
into serosa
T4 – Invasion
into adjacent
structures

C

D

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future
of TNM. Ann Surg Oncol. 2010;17(6):1471-4.

Figure 5. Dukes’ Classification of Colon Cancer

10
Dukes’ Stages of Bowel Cancer. Available from: http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/treatment/dukesstages-of-bowel-cancer [Accessed 28th September 2016].

d)

Treatment for Colorectal Cancer
For the majority of cases, the mainstay of treatment for colorectal cancer is

excision of the tumor either surgically or endoscopically. Other adjunct agents include
chemotherapy, radiation therapy, or targeted therapy. Typically precursor colorectal
adenomas can be removed via colonoscopy and very early stage cancers can be removed
by local excision. Early stage disease is best treated surgically with resection of the tumor
and surrounding tissue to ensure adequate removal of the cancer as demonstrated by the
absence of tumor cells at the resected surgical margin. Chemotherapy, either adjuvant or
neoadjuvant, may be indicated in patients presenting with more advanced disease defined
in the case of colon cancer by lymph node metastasis. Chemotherapy can be administered
systemically, regionally, or by hepatic artery infusion in cases where the cancer has
metastasized to the liver. Commonly used chemotherapeutic agents include 5-flurouracil,
leucovorin, capecitabine, oxaliplatin and irinotecan. Often, two or more of these drugs are
given in combination to increase their efficacy.
Not all CRCs respond to traditional chemotherapy. As research has advanced to
understand the genetic and protein changes involved in the development of CRC, newer
drugs have been developed to target these changes. Classes of targeted drugs include
those that 1) act to stop blood vessel formation by targeting vascular endothelial growth
factor, a protein involved in angiogenesis, 2) drugs that target epidermal growth factor
receptor, a protein present on the cell surface that is involved in the growth of cancer
cells, and 3) drugs that inhibit kinase activity, proteins on or near the surface of cells that
transmit signals to the control center of cells.
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In patients with isolated or few metastases to the liver or lung, it is possible to
surgically remove these with the primary tumor. For other forms of advanced disease,
newer techniques such as ablation and embolization therapy can be used to destroy the
tumor. These methods of treatment are often reserved for patients who are unable to have
surgery for other reasons, or whose disease burden is so great it cannot be removed
surgically. Palliative care is a form of medical care used for symptom control in advanced
and end stage disease in patients. Palliative care can be operative or non-operative
depending on the symptoms experienced with the overall aim to improve a patient’s
quality of life.
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CHAPTER II
MOLECULAR MECHANISMS OF COLORECTAL CARCINOGENESIS

Colorectal cancer presents in one of three major forms: inherited, sporadic, and
familial. Inherited and familial forms of CRC are from germline mutations, with inherited
CRC accounting for <10% and familial accounting for approximately 25% of all CRC
cases. Common inherited conditions leading to the development of CRC include Familial
adenomatous polyposis (FAP), its variant Gardner syndrome, Lynch syndrome
(hereditary non-polyposis colon cancer), and Peutz-Jeghers syndrome. Each of these
syndromes are caused by inherited mutations in genes associated with cell growth or
DNA repair. Sporadic CRC, derived from somatic or acquired gene mutations, is by far
the most common presentation of CRC, accounting for up to 70% of all cases. It is not
associated with family history.
In CRC, three distinct pathways of genomic instability underlie the development
of sporadic and inherited colorectal carcinogenesis: chromosomal instability (CIN),
microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP)
pathway. This thesis will focus only on sporadic CRC and the CIN pathway.
The CIN pathway, also known as the adenoma-carcinoma sequence, follows a
predictable progression of genetic mutations and corresponding histologic
13

changes. It is well recognized that the majority of sporadic CRC’s develop from
adenomas or polyps. Genetic changes drive normal colonic epithelium to invasive cancer
through a four-step progression: firstly, transformation of normal epithelium to an
adenoma or polyp, proceeding to an in-situ carcinoma, and ultimately to an invasive and
metastatic adenocarcinoma. The adenoma-carcinoma sequence is the most common
colorectal polyp pathway accounting for around 80% of cases, the other 20% being via
the serrated polyp pathway.
In this adenoma-carcinoma sequence, normal mechanisms regulating epithelial
renewal are disrupted. Under normal conditions, surface cells are lost due to apoptosis,
cell proliferation occurs at the crypt base, and at the luminal surface cells cease
proliferation and terminally differentiate. As adenoma size increases, this normally
ordered process in increasingly disrupted, the cells become dysplastic and develop
invasive potential. Since the 1970’s indirect evidence such as pathologic, epidemiologic
and observational data has supported this sequence of events. Firstly, residual benign
adenomatous tissues have been found in resected carcinoma specimens. Secondly,
malignant foci have been observed in advanced adenomas. Thirdly, longitudinal studies
have shown that benign polyps develop into invasive CRC over time. Stryker et al.
observed 226 patients with colonic polyps >1cm in diameter who declined surgical or
endoscopic resection. At 20-year follow-up, patients had a 24% risk of developing
invasive adenocarcinoma at the site of the index polyp, and a 35% risk of carcinoma at
any colonic site. (25) The National Polyp Study also confirmed the hypothesis that CRC
arises from adenomas by showing that endoscopic polypectomy reduced the risk of
developing a subsequent CRC. (5)
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There are well-defined molecular genetic steps within the CIN pathway that
contribute to the development of invasive carcinoma whereby mutational activation of
oncogenes and inactivation of tumor suppressor genes occur. (26) The initial step in the
CIN pathway is identification of a dysplastic aberrant crypt focus, a microscopic mucosal
lesion that precedes the development of a polyp. (27, 28) At this stage, mutations in the
adenomatous polyposis coli (APC) gene cause activation of the Wnt signaling pathway.
Progression to late adenoma and early stage carcinoma requires the activation of the
KRAS proto-oncogene. Additional malignant transformation is caused by mutations in
TP53, PIK3CA, and TGF-β pathway genes (Figure 6). (29-31) Key principles defining
the CIN pathway include multiple genetic mutations, the step-wise progression from
normal mucosa to invasive carcinoma, and aberrant crypt foci of the colon as the
precursor to adenoma formation. (28, 32)
Recent evidence within the last 15 years defines an alternative route to the
development of CRC. The serrated polyp pathway is responsible for ~20% of all sporadic
colorectal cancers. Hyperplastic polyps were previously regarded as benign lesions with
little or no malignant potential. It is now recognized that these polyps form part of a
heterogeneous group, termed serrated polyps, which are characterized by their sawtoothed appearance. This group contains three premalignant lesions: the hyperplastic
polyp, the traditional serrated adenoma, and the sessile serrated adenoma. It is believed
that the sessile serrated adenoma is the main precursor lesion within this pathway leading
to the development of CRC (Figure 7). Similar to the CIN pathway, a series of molecular
mutations contribute to the development of sporadic CRC. Such mutations include BRAF
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Figure 6.The Chromosomal Instability Pathway (CIN) in Colon Cancer
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Multistep genetic model of colorectal carcinogenesis. The initial step is formation of aberrant crypt foci following mutations in the
APC gene. Progression to larger adenomas and early carcinoma require activating mutations in KRAS oncogene TP52 and loss of
heterozygosity at chromosome 18q Chromosomal instability increases with tumor progression.
Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059-72.

Figure 7. The Serrated Polyp Pathway in Colon Cancer
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Proposed serrated polyp pathway to MSI colorectal cancer. Characteristic crypt alterations, and epigenetic and genetic alterations

Crockett SD, Snover DC, Ahnen DJ, Baron JA. Sessile serrated adenomas: an evidence-based guide to management. Clin
Gastroenterol Hepatol. 2015;13(1):11-26 e1.

mutation and CpG island methylation which causes inactivation of the MLH1 mismatch
repair gene resulting in microsatellite instability (MSI). Sessile serrated adenomas are
also believed to be a significant contributor to development of CIMP and microsatellite
stable (MSS) carcinomas.(33, 34)
Defects in mismatch repair genes (MMR) lead to MSI carcinomas. MSI colorectal
carcinomas account for ~15% of all CRC tumors. The term microsatellite refers to
repeated short sequences of DNA. In normal conditions within cells MMR enzymes
correct spontaneous errors within these regions during DNA replication. Defects in MMR
genes result in a reduced capacity of these cells to repair specific types of DNA damage.
The majority of MMR defects in sporadic CRC are due to epigenetic silencing of Mut L
homologue 1 (MLH1) gene expression by promoter hypermethylation.(35) Two
phenotypes of MSI exist. The first is MSI-High, defined as the presence of instability in
greater than 30% of markers and characteristically cause silencing of MLH1. Patients
with MSI-High colorectal cancer tend to be younger, and despite the histological features
of poor differentiation, patients tend to have a better long-term prognosis than those with
MSS cancers. MSI-low cancers, defined as the presence of instability in 10-29% of
markers, do not differ from microsatellite stable tumors and typically arise from the CIN
pathway.(26) Hereditary Non-Polyposis Colorectal Cancer (HNPCC), as part of Lynch
Syndrome, is an autosomal dominant disease caused by germline mutations in MMR
genes. MSI resulting from this genetic defect is seen in more than 95% of all patients
with HNPCC. HNPCC accounts for up to 5% of all CRC cases.
CpG island methylated phenotype (CIMP) pathway is the third, and most recently
described, major molecular pathway involved in colorectal carcinogenesis. A CpG site is
18

a region of DNA where cytosine occurs next to guanine. DNA methylation occurs at
these sites and 80-90% of all CpG are methylated. The remaining 10% form cluster
“islands” in the promoter region and are unmethylated in the germ line. When vast
hypermethylation of the promoter CpG island sites occur, tumor suppressor genes are
silenced and cancer develops. The precursor lesion is considered to be a sessile serrated
adenoma.(36)
Understanding the molecular and genetic differences involved in each pathway in
colorectal tumorigenesis, as described above, can be difficult. Figure 8 shows a schematic
representation of several of the overlapping pathways involved in the development of
colorectal carcinoma.(37) In conclusion sporadic CRC develops via a multistep process
of specific genetic changes driving tumorigenesis. Single, specific germline mutations
underlie inherited syndromes, whereas sporadic CRC results from accumulation of
somatic mutations. The three major molecular carcinogenic pathways are the
chromosomal instability, microsatellite instability, and CpG Island methylated phenotype
pathways. Abnormalities underlying familial CRC remain poorly understood.
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Figure 8. Schematic representation of several overlapping pathways involved in the
development of colorectal cancer

Red circles represent mechanisms based on tumor suppressor and mutator pathways.
Blue circles represent mechanisms based on the precursor lesion (CIN and Serrated
polyp pathways).
Yellow circles represent currently poorly characterized pathways.

Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol.
2011;42(1):1-10.

20

Kirsten rat sarcoma viral oncogene homolog (KRAS) in Colorectal Cancer
1) History
Ras is a family of small guanosine-nucleotide-binding proteins (G-proteins)
involved in transmitting signals within cells. In humans, the three most clinically notable
members of the Ras family of genes are HRAS, KRAS and NRAS. KRAS and HRAS,
the first of the two Ras genes were identified from studies of cancer-causing viruses,
namely Kirsten and Harvey sarcoma virus, respectively. (38) These viruses were
originally discovered in rats by Jennifer Harvey and Werner Kirsten in the 1960’s,
coining the name Rat sarcoma. (39, 40) Discovery was made in 1982 that a single
nucleotide substitution within KRAS gene was responsible for activating mutation in
human cells and transformation of the subsequent protein resulted in various
malignancies. (41-44)
2) Function
The protein product of the normal KRAS gene performs an essential function in
normal tissue signaling. Mutation within the gene is implicated in the development of
many cancers, in particular, colorectal cancer. KRAS mutations have been observed in
some 10% of colorectal adenomas, up to 50% of colorectal adenomas displaying severe
dysplasia, and 35-45% of colorectal carcinomas.(45-47) Located on human chromosome
12, KRAS is a membrane-bound guanosine triphosphate/guanosine diphosphate
(GTP/GDP)-binding protein. It contains four coding exons and one 5” non-coding exon.
Single nucleotide point mutations in KRAS occur in codons 12 and 13 of exon 2, in
codon 146 in exon 4, and rarely in codon 61 of exon 3. (48, 49)
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KRAS acts as a molecular on/off switch downstream of growth factor receptors
such as the epidermal growth factor receptor (EGFR). Under normal physiologic
conditions, activation of KRAS occurs from upstream signaling by the exchange of
bound GDP for GTP. KRAS is a membrane-bound GTPase that cycles between the active
GTP-bound form and the inactive GDP-bound form. This process is transient due to
GTPase-activating protein (GAP) mediated GTP hydrolysis. Upon conversion of GTP to
GDP, KRAS is turned off. When mutations occur, the intrinsic activity of KRAS GTPase
is impaired which prevent GAPs from GTP hydrolysis, locking the KRAS protein in its
active GTP-bound form. This results in over activation of downstream proliferative
signaling pathways. (50) The consequence of this includes increased cell proliferation,
reduced apoptosis, altered cell metabolism and changes in the tumor microenvironment.
Mitogen-Activated Protein Kinase (MAPK) Pathway
The Mitogen-activated protein kinase (MAPK) pathway is a chain of proteins
within a cell that communicates signals from cell surface membrane receptors to the
DNA in the nucleus of a cell. The communication from the cell surface to the nucleus
occurs through the addition of phosphate groups to neighboring proteins. These steps act
as “on” or “off” switches, however; when a protein within the pathway is mutated, it can
cause the pathway to become stuck in either the “on” or “off” position. This is typically a
necessary step in the development of cancer and is frequently dysregulated in
approximately one-third of all cancers.
There are three major subfamilies, namely the extracellular-signal-regulated
kinases (ERK MAPK, Ras/Raf1/MEK/ERK), the c-jun N-terminal kinase or stress-
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activated protein kinases (JNK or SAPK), and MAPK14. They are located downstream of
growth-factor receptors, including epidermal growth factor receptors. Overexpression and
activation of this receptor is commonly observed in CRC. Of these sub families, the ERK
MAPK pathway is one of the most important for cell proliferation. Several protooncogenes transduce the signals that promote cell growth and differentiation within this
cascade. (51) It is for these reasons that the ERK MAPK pathway is believed to be
implicated in the pathogenesis, progression, and oncogenic behavior of CRC. (52) For
this reason, kinases within the ERK MAPK pathway have the potential to be used as
targets for the treatment of CRC.
The MAPK pathway comprises of three-tiers of protein kinases, MAPK1 - 3, in
which the top tier activates the subsequent level, which in turn activates the next level. In
order for activation of the downstream MAPK within the pathway, it is phosphorylated
by mitogen-activated protein kinase kinase (MAP2K), which in turn has been activated
by mitogen-activate protein kinase kinase kinase (MAP3K).
The initial step to activate the ERK MAPK pathway is through extracellular
signals transmitted via protein kinase C (PKC) or Ras. PKC activity promotes binding of
GTP to members of the Ras family, leading to activation of Raf. Raf (MAP3K)
phosphorylates MEK1 and MEK2 (MAP2K), which in turn phosphorylates ERK 1/2
(MAP1K). MEK1 and MEK2, also known as ERK kinases, are dual-specificity protein
kinases that function to control cell growth and differentiation within the MAPK cascade.
Activation of ERK results in migration of enzymes to the nucleus of the cell, where
phosphorylation of transcription factors regulate genes that increase cell proliferation and
reduce apoptosis (Figure 9).(53)
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Figure 9. Schematic Overview of the ERK MAPK Pathway

Extracellular signal proteins bind to receptor tyrosine kinases. K-Ras is activated by
binding to GTP. Active K-Ras binds to Raf1 and initiates a phosphorylation cascade.
Downstream transcription factors are affected leading to altered gene expression.

Raf = MAP3K

MEK 1/2 = MAP2K
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ERK 1/2 = MAP1K

CHAPTER III
MICRORNAs AND COLORECTAL CANCER

a)

Overview and Biogenesis
microRNAs (miRNAs) are recognized to play a crucial role in the regulation of

cell function through specific interactions with their messenger RNA (mRNA)
counterparts. They are small, naturally occurring, non-protein coding RNA molecules
that downregulate gene expression and affect subsequent protein expression. A single
miRNA can bind to and regulate many different mRNA targets and, conversely, several
different miRNAs can bind to and jointly control a single mRNA.
miRNAs are transcribed in the nucleus as large RNA precursors called primarymiRNAs (pri-miRNAs) (54). These pri-miRNAs are enzymatically cleaved in the nucleus
by the enzyme Drosha into precursor miRNA (pre-miRNA). (55) The resulting
approximately 70-nucleotide pre-miRNA are folded into stem-loop structures. These premiRNAs are then exported into the cytoplasm by the GTP-dependent transport protein
exportin 5. (56) Once in the cytoplasm, they undergo additional processing by the
enzyme Dicer to generate the mature double-stranded miRNA approximately 22
nucleotides in length. Dicer also initiates the formation of the RNA-induced silencing
complex (RISC). (57) It is in this final part of miRNA biogenesis that the leading miRNA
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strand is incorporated into the RISC complex, which is then guided into the
complementary 3’ or 5’ untranslated region of the target mRNA. The RISC is responsible
for the gene silencing observed due to miRNA expression and RNA interference (Figure
10). (58) miRNAs cause translational repression, target degradation or gene silencing and
therefore affect subsequent protein expression.
miRNAs exhibit a variety of crucial regulatory functions related to cell growth,
development, and differentiation. (59, 60) miRNAs can function as either tumor
suppressor genes or oncogenes. Overexpression of miRNAs in cancer may function as
oncogenes and promote oncogenesis by down-regulating tumor suppressors or other
genes involved in cell differentiation. In contrast, miRNAs in cancer may function as
tumor suppressors by inhibiting oncogenesis via down-regulation of proteins with
oncogenic qualities. (61, 62) Studying the specific function of miRNAs in human
carcinogenesis will help to identify new targets for cancer research, diagnosis and
treatment.
b)

microRNAs as Biomarkers for Diagnosis of Colorectal Cancer
Biological markers or biomarkers are defined as “a characteristic that is

objectively measured and evaluated as an indicator of normal biological processes,
pathogenic processes or pharmacological responses to a therapeutic intervention”. (63)
Biomarkers, such as blood, urine and cerebrospinal fluid, can be used for screening,
diagnosis, and predicting prognosis in human diseases. (64) Plasma and serum are
components of blood and are a commonly used in diagnostic assays. Serum is of similar
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Figure 10. microRNA Biogenesis

MicroRNAs are transcribed from DNA into pri-microRNA and are then processed by
Drosha into the pre-microRNA. The pre-microRNA is transported into the cytoplasm by
Exportin-5 and processed by Dicer and integrated into the RNA-induced silencing
complex (RISC). The complementarity of the microRNA-seed sequence determines the
effect on the target mRNA: a 100% match results in the degradation of the mRNA
whereas an 80% match inhibits protein production. Drosha and Dicer are RNAprocessing enzyme located in the nucleus or cytoplasm, respectively. miRNAs circulate in
various secreted extracellular vesicles, such as microvesicles, apoptotic bodies and
exosomes, or bound to proteins.
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composition to plasma except for lacking clotting factors. Both plasma and serum contain
hormones, glucose, electrolytes, antibodies, antigens and nutrients making them ideal
media in diagnostic testing. (65) The most commonly used blood-based CRC biomarker,
carcinoembryonic antigen (CEA), which is used for post-operative surveillance and for
monitoring response to therapy, lacks sensitivity and specificity for screening or for the
detection of recurrent CRC (see also pg. 6-7). (21)
Significant advances have occurred in the field of tumor-associated miRNAs
since their first discovery in plasma as the number of studies investigating their
expression has markedly increased in recent years. (66, 67) Although colonoscopy
remains the gold standard screening test for the diagnosis of CRC, the evaluation of
miRNA within plasma and/or serum of circulating blood has provided a new area for
biomarker research. (4, 6, 7, 68)
miRNAs are stable in extracellular fluid since they are protected from RNases by
virtue of being bound to argonaute proteins. (69) Discovery of dysregulated miRNA
expression has been identified in colorectal, esophageal, lung, liver, pancreatic, bladder,
ovarian, and gastric cancers.(70, 71) miRNAs have been identified in numerous body
fluids, such as plasma, saliva, feces, and urine. (67, 72) These factors suggest that
miRNAs can be used as biomarkers for cancer and other disease states. (73)
The miR-17-92 cluster, also known as oncomiR-1 was the first miRNA
“oncogene” to be described. (74) Six miRNAs form this miR-17-92 cluster: miR-17,
miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 and are known to be
dysregulated in many cancers. (75) miR-17-92 is overexpressed in both tissue and serum

28

of CRC patients. (76, 77) In a recent systematic review, 5 of the 6 members of this
cluster, with the exception of miR-19b-1, were significantly upregulated in the serum or
plasma of CRC patients as compared to controls in 8 studies. (77-84) The most predictive
miRNA was miR-92a with area under the curve (AUC) values ranging from 0.786 to
0.890, 65.5 to 89% sensitivity and 70 to 82.5% specificity. The remaining member of the
cluster, miR-19b-1, was also significantly upregulated in CRC patients when combined
as a 2 miRNA panel together with miR-19a, with an AUC of 0.82, 78.57% sensitivity and
77.36% specificity. (85) These data support the oncogenic role of the miR-17-92 cluster
in CRC.
miR-21 has been identified in multiple studies to be upregulated in CRC patients
as compared to healthy controls. Kanaan et al. identified miR-21 as a biomarker for CRC.
(72) Validated CRC tissue miRNAs were evaluated in a plasma test set consisting of 30
CRC patients and 30 healthy controls. The most dysregulated tissue miRNAs were then
validated in different cohort of 20 CRC patients with 20 age- and race-matched subjects
without CRC. In the plasma test group, miR-21 differentiated CRC patients from controls
with an AUC 0.910 and a 90% specificity and sensitivity. (72) Following this, 6 groups
reproduced similar results with AUC’s ranging from 0.647 – 0.927, 65 – 87.5%
sensitivity and 74.4 – 93.2% specificity. Although these data were promising,
dysregulation of miR-21 has been described in many other cancers. (86-93) There is
therefore need for a plasma miRNA profile specific for CRC.
miR-29a is another miRNA that has been reported to be upregulated in CRC
patients in 3 studies. (78, 80, 94) miR-29a is part of the miR-29 family (miR-29a, miR29b, miR-29c). Interestingly, another member of the miR-29 family, miR-29b, was
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observed to be downregulated in CRC compared to control subjects in 2 studies. (95, 96)
Members of the miR-29 family exhibit differential regulation, implying that their
functional relevance may not be identical. (97) miR-29b has been shown to function as a
tumor suppressor in various cancers and diseases (98), while miR-29a has been shown to
act as a tumor suppressor in lung cancer (99), but as an oncogene in CRC, ovarian and
breast cancer. (100, 101)
In order to reduce CRC associated mortality, the ideal biomarker would be able to
identify individuals with both early stage CRC and its precursor lesion, the colorectal
advanced adenoma (CAA), from healthy control subjects. CAA are defined as adenomas
with a villous component, those with high grade dysplasia, or size greater than 0.75cm
size in diameter. (102) In the studies included in the same recent review, 7 studies
evaluated miRNAs found to be significantly dysregulated in CRC patients, and in 420
patients with CAA. Five of these 7 studies reported miRNA panels significantly
upregulated in CAA as compared to healthy controls. (78, 81, 82, 103, 104) One study
also identified a panel of 5 miRNAs that distinguished between CRC and CAA with an
AUC of 0.856. (103) The remaining 2 studies found no significant differences in miRNA
profile between CAA and healthy controls. (85, 105)
Identification of numerous miRNAs associated with colorectal carcinogenesis
demonstrates that miRNAs can distinguish patients with CRC from healthy controls with
high sensitivity and specificity comparable to that of other common, currently used
invasive screening methods for CRC.
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However, no single miRNA has yet been identified as an ideal biomarker for the
diagnosis of CRC. With deaths from colorectal cancer amongst the leading cause of
cancer deaths worldwide, there is an emphasis to increase screening, and therefore
identify early, less invasive stage disease, and to improve survival. For this purpose,
miRNAs have the potential in the future to be used as a relatively non-invasive, inexpensive, blood-based marker for the detection of CRC.
c)

miRNAs and Colorectal Cancer Prognosis
Currently, clinicopathologic tumor staging based on the tumor–node–metastasis

(TNM) system is the basic prognostic marker for CRC clinical outcomes. The TNM
system describes the degree to which the tumor has invaded the bowel wall and spread to
the regional lymph nodes as well as metastasized to distant organs. Although the TNM
staging system is the mainstay of assessing prognosis, this classification has weaknesses.
Inadequate examination of lymph nodes may lead to under staging of the tumor and
subsequent inadequate treatment.(106) Additionally, histologically identical CRC
patients may have different genetic and epigenetic backgrounds that lead to distinct
disease progression and clinical outcomes. Unfortunately, no prognostic marker is
currently available for identifying the patients who would benefit from more-aggressive
treatments. Recent epigenetic studies have suggested that miRNAs may help to better
categorize CRC subtypes and predict outcomes.
miR-21 is one of the most studied and most promising prognostic miRNAs in
CRC. Increased levels of miR-21 have been correlated with CRC cell proliferation,
invasion, lymph node metastases, and advanced clinical stage.(107-111)

31

Members of the miR-29 family exhibit differential regulation, implying that their
functional relevance may not be identical. miR-29a has been identified to be significantly
elevated in patients with liver metastases in multiple studies,(78, 112, 113) however; in
other studies, upregulation of miR-29a was associated with a better 12 month
survival.(114, 115) In addition, elevated levels of another member of the miR-29 family,
miR-29b, was associated with higher 5-year disease free and overall survival.(116)
Other miRNAs suggestive of poor prognosis include miR-34b/c, miR-155 and
miR-130b. Increased expression of each of these miRNAs in CRC tissue is associated
with poor prognosis and more advanced stage tumors.(117-119) Downregulation of miR139-3p in CRC tissue samples was associated with poor survival, especially in those
patients with early stage (TNM I and II) CRC. (120)
In order to develop these miRNAs as prognostic markers in CRC, further studies
validating these miRNAs are required. It is also important to understand the underlying
mechanisms of each prognostic biomarker, and its respective molecular function, both in
order to support their clinical use and provide therapeutic targets.
d)

miRNAs and Response to Chemotherapy in Colorectal Cancer
Primary treatment of stage I to III CRC’s is surgical resection of the primary

tumor together with the regional lymph nodes. In patients with high risk stage II and
stage III disease, adjuvant chemotherapy should be considered. A common chemotherapy
agent used to treat CRC is 5-fluorouracil (5-FU) a pyrimidine analog. 5-FU metabolism is
complex, requiring multiple enzymes, including thymidylate synthase (TS). TS catalyzes
the conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate
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(dTMP), which is one of the three nucleotides that forms thymine (121). Thymine is a
nucleic acid that is necessary for DNA replication. 5-FU acts to irreversibly inhibit TS,
essentially starving rapidly dividing cells by halting DNA production.
In addition to the potential use of miRNAs as biomarkers for detection and for
prognosis in CRC patients, several studies have identified miRNAs to predict the
sensitivity of CRC to chemotherapy. The key to successful treatment is predicting
response to chemotherapy. It has been suggested that 5-FU could alter miRNA
expression in colon cancer cells after exposure and treatment thereby affecting the
mechanisms involved in 5-FU metabolism. (122)
A recent review by Hollis et al. identified ten miRNAs to be associated with
chemosensitivity. Of these, upregulation of miR-21, miR-153, miR-19a, miR-106a, miR130b, and miR-484 was associated with increased resistance to 5-FU and other common
chemotherapy agents. Resistance to chemotherapy was also observed when the following
four miRNAs, miR-129, miR-15b, miR-1915, and miR-122 were down-regulated.
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CHAPTER IV
COLORECTAL CANCER CELL LINE SCREENING

a)

Introduction
Cell lines are a common experimental model used to study biological mechanisms

involved in various diseases. In-vitro cell line studies allow for the investigation of
signaling pathways, functional processes, identification of molecular markers of disease,
and testing of cancer therapeutics. As previously described, cancer occurs when a somatic
cell undergoes a mutation disrupting normal cell cycling resulting in uncontrolled
proliferation. Immortalized cell lines are a population of cells that can be grown for
prolonged periods due to similar mutations that enable cells to continually proliferate. It
is for this reason that cell lines provide an almost unlimited supply of cells with similar
genotypes and phenotypes for study. The main advantage of this is consistency,
reproducibility, and the associated relative low-cost. However; questions often arise over
to what extent the cells actually resemble their tissue of origin after years in culture. The
most common way to generate an immortalized cell line is by isolating cells from a
naturally occurring cancer. Whilst cell lines generated in this fashion are known to have
originated from a specific tissue type, the cells have undergone significant mutation
allowing for indefinite proliferation. However; for these reasons, caution must be applied
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when interpreting results as the biology of the cell can be altered.
By utilizing well established immortalized CRC cell lines, we are able to
manipulate cancer pathology in order to gain a better understanding of cancer biology.
We have chosen to characterize the differential expression of miRNAs in CRC as
compared to a normal colon epithelial cell line in order to identify potential therapeutic
targets for intervention.
b)

miRNA Screening of Colorectal Cancer Cell Lines
Five immortalized colorectal cell lines, four sporadic colorectal cancer cell lines,

representing each stage of the Modified Dukes’ classification, and one normal colon
epithelial cell line used for comparison were studied. Our aim was to characterize the
differential expression of miRNAs in CRC cell lines as compared to the normal colon
epithelial cell line in order to identify potential therapeutic targets for intervention (see
pg. 59 for methods).
Comparison of miRNA expression between combined localized stage cancer
(Dukes’ A and B) and normal colon epithelium, and metastatic stage cancer (Dukes’ C
and D) and normal colon epithelium was performed (n=4). In order to achieve adequate
power and group size of four, each sporadic colorectal cancer cell line, SW1116, SW480,
HT-29 and T84 (Dukes’ A – D, respectively), was screened twice for miRNA expression
and CCD841, normal colon epithelium, was screened four times.
We identified 190 miRNA to be significantly dysregulated, of which 36 were upregulated and 154 were downregulated in localized stage CRC (Dukes’ A and B)
compared to normal colon epithelium. Similarly, 231 miRNAs were significantly
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dysregulated in metastatic stage CRC (Dukes’ C and D) compared to normal colon
epithelium, 39 up- and 192 and downregulated, respectively (Table 2). Fold change was
calculated to assess the magnitude of change between the two groups compared. In
addition to the p-value, a change was deemed significant when the fold change was > 2fold up or down. The twenty most significantly up-regulated and downregulated miRNA
for each comparison (localized vs. normal and metastatic vs. normal) with their
corresponding fold change are shown in tables 3 & 4. Representative waterfall plots are
shown in figures 11 & 12.
Of interest, five of the top eight most significantly up-regulated miRNAs in
localized stage CRC compared to normal colon epithelium were miR-200a, miR-429,
miR-141, miR-200b, and miR-200c. Similarly, in metastatic stage CRC compared to
normal colon epithelium, five of the top six most significantly up-regulated miRNAs
were these same five miRNAs (Table 5).
Single assay miRNA expression was performed in each of the cell lines to
confirm our findings from screening. Here, miRNA expression in each individual
colorectal cancer cell line was compared to the normal colon epithelial cell line.
We confirmed miRNA expression of these five miRNAs to be significantly upregulated in all colorectal cancer cell lines compared to the normal colon epithelial cell
line (Table 6). The Dukes’ C CRC cell line had the largest up-regulation of all five miR200 family members compared to the normal colon epithelial cell line than any of the
other Dukes’ stage cancer cell lines, and were selected for further study.
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Table 2. Significantly Dysregulated miRNAs in Colorectal Cancer Cell Lines Compared to a Normal Colon Epithelial Cell Line

Cell Line Comparison vs. Normal
Colon Epithelium

No. of Dysregulated
miRNA*

Up-Regulated (n)

Downregulated (n)

Localized Stage Cancer
(Dukes’ A SW1116 and B SW480)

190

36

154

Metastatic Stage Cancer
(Dukes’ C HT-29 and D T84)

231

39

192

37
*

p<0.05 Student t-test

Table 3. The Most Significantly Up-regulated and Downregulated miRNAs in Localized Colorectal Cancer Cell Lines (Dukes’ A
SW1116 and B SW480) Compared to the Normal Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change
Up-regulated

Downregulated
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miRNA

Fold Change

p-value

miRNA

Fold Change

p-value

miR-200a
miR-429
miR-203
miR-135b
miR-141
miR-200b
miR-95
miR-200c
miR-518f
miR-9
miR-182
miR-183
miR-375
miR-302a
miR-142-3p
miR-372
miR-96
miR-192
miR-135a
miR-196b

18830
11414
7406
6566
6478
3756
3380
2688
1289
1165
1129
546
532
368
348
272
151
124
119
105

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.041
<0.0001
<0.0001
<0.0001
<0.0001
0.003
0.008
0.045
<0.0001
0.009
<0.0001
0.003

miR-143
miR-329
miR-654-3p
miR-134
miR-193a-5p
miR-214
miR-541
miR-485-3p
miR-485-5p
miR-296
miR-409-5p
miR-654
miR-379
miR-199a
miR-410
miR-493
miR-495
miR-127
miR-369-5p
miR-655

-4545
-5000
-5556
-7143
-10000
-10000
-11111
-16667
-16667
-25000
-33333
-33333
-33333
-50000
-50000
-50000
-50000
-100000
-100000
-100000

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Table 4. The Most Significantly Up-regulated and Downregulated miRNAs in Metastatic Colorectal Cancer Cell Lines (Dukes’ C HT29 and D T84) Compared to the Normal Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change
Up-regulated

Downregulated
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miRNA

Fold Change

p-value

miRNA

Fold Change

p-value

miR-200a
miR-429
miR-200b
miR-141
miR-203
miR-200c
miR-135b
miR-375
miR-183
miR-182
miR-142-3p
miR-215
miR-196b
miR-192
miR-194
miR-96
miR-582-5p
miR-95
miR-135a
miR-10b

35668
30476
8862
6531
6347
4171
3377
2490
759
754
577
454
407
296
179
109
95
88
77
42

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.019
0.001
<0.0001
<0.0001
<0.0001
0.001
<0.0001
0.022
<0.0001
0.009

miR-486-3p
miR-504
miR-34c
miR-542-3p
miR-99a
miR-100
miR-424
miR-450a
miR-541
miR-130a
miR-199a
miR-299-5p
miR-323-3p
miR-369-3p
miR-409-5p
miR-485-3p
miR-485-5p
miR-654
miR-654-3p
miR-137

-250
-250
-333
-333
-333
-500
-500
-500
-500
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000

<0.0001
0.002
<0.0001
<0.0001
<0.0001
<0.0001
0.002
0.001
<0.0001
<0.0001
<0.0001
0.001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.004

Figure 11. Waterfall Plot of the Significantly Dysregulated miRNAs in Localized
Colorectal Cancer Cell Lines (Dukes’ A SW1116 and B SW480) as Compared to the
Normal Colon Epithelial Cell Line (CCD 841)
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Figure 12. Waterfall Plot of the Significantly Dysregulated miRNAs in Metastatic
Colorectal Cancer Cell Lines (Dukes’ C HT-29 and D T84) as Compared to the Normal
Colon Epithelial Cell Line (CCD 841)
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Table 5. miR-200 Family Expression in Colorectal Cancer Cell Line Screening

Cell Line Comparison vs. Normal
Colon Epithelium

Localized Stage Cancer
(Dukes’ A SW1116 and B SW480)
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Metastatic Stage Cancer
(Dukes’ C HT-29 and D T84)

miRNA

Fold Change

p-value

miR-200a

18830

<0.0001

miR-200b

3756

<0.0001

miR-200c

2688

<0.0001

miR-141

6478

<0.0001

miR-429

11414

<0.0001

miR-200a

35668

<0.0001

miR-200b

8862

<0.0001

miR-200c

4171

<0.0001

miR-141

6531

<0.0001

miR-429

30476

<0.0001

Table 6. Single Assay miRNA Validation of miR-200 Family in Colorectal Cancer Cell Lines Compared to a Normal Colon Epithelial
Cell Line (CCD 841)

Cell Line Comparison vs. Normal Colon Epithelium

miRNA

Dukes’ A
SW1116

Dukes’ B
SW480

Dukes’ C
HT-29

Dukes’ D
T84
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Fold
Change

p-value

Fold
Change

p-value

Fold
Change

p-value

Fold
Change

p-value

miR-200a

1541

<0.0001

1186

<0.0001

15104

<0.0001

1410

<0.0001

miR-200b

4238

<0.0001

3989

<0.0001

22039

<0.0001

3340

<0.0001

miR-200c

3303

<0.0001

3752

<0.0001

7323

<0.0001

5216

<0.0001

miR-141

23207

<0.0001

27067

<0.0001

35026

<0.0001

19135

<0.0001

miR-429

4729

<0.0001

3171

<0.0001

50262

<0.0001

7193

<0.0001

c)

Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Germany) is an intuitive web-

based application for quickly analyzing and accurately interpreting the biological
meaning in your genomic data. It allows for the input of sequencing, Real-Time PCR,
and microarray data. Among many of its features, IPA is able to combine filtering tools
and microRNA-mRNA content to provide insight into the biological effects of identified
miRNAs. It is also identifies genes that are shown to be activated in a pathological
condition and highlights canonical and non-canonical pathways associated with
biological processes. IPA allows for identification of promising targets for therapeutic
development.
From our microarray screening, IPA was able to identify miRNAs and the
associated pathways they targeted, relevant to our data. The signaling pathway most
closely linked to the colorectal cancer cell line screening data was the ERK MAPK
pathway as previously described. miR-200b and miR-141 were identified as being
strongly upregulated within this pathway (Figure 13).
We used a miRNA target prediction program to identify targets associated to
these dysregulated miRNAs. miRTarBase is a database of miRNA-target interactions that
are experimentally validated by reporter assay, western blot, microarray and nextgeneration sequencing experiments. It provides up to date information and combines the
largest amount of validated miRNA-target interactions by comparing content from other
similar target databases. miRTarBase identified all five miRNAs (miR-200a, miR-200b,
miR-200c, miR-141 and miR-429)
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Figure 13. ERK MAPK Signaling and miRNAs Results from Ingenuity Pathway Analysis
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The networks were generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®,QIAGEN Redwood City,
www.qiagen.com/ingenuity).

Figure 14. miR-200a Targets Identified by miRTarBase
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miRTarBase is available at http://miRTarBase.mbc.nctu.edu.tw/

Figure 15. miR-200 Family and its Target RASSF2 as Identified by miRTarBase
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miRTarBase is available at http://miRTarBase.mbc.nctu.edu.tw/

significantly dysregulated in our colorectal cancer cell lines compared to normal colon
epithelium to have multiple targets. Of interest, all five of these miRNAs were validated
targets of the same gene, Ras associated domain-containing protein 2 (RASFF2) (Figure
14 & 15).
d)

microRNA-200 Family
The miR-200 family consists of five members, miR-200a, miR-200b, miR-200c,

miR-141, and miR-429. They form two clusters located in two different genomic regions.
Cluster 1, miR-200a, miR-200b, and miR-429, is located on chromosome 1, whereas
miR-200c, and miR-141 is located on chromosome 12. The seed sequence of a miRNA is
the second to eighth nucleotide region at the 5’ end of the mature miRNA, that generates
the specificity of each miRNA to its target mRNA. Additionally, the miR-200 family can
be divided into two functional groups, based on their seed sequences. Functional group 1,
miR-200b, miR-200c, and miR-429, and functional group 2, miR-200a and miR-141,
with each functional group sharing the same seed sequence (Figure 16). The miR-200
family has been widely investigated in regards to its role in cancer, and is known to be
well associated with epithelial to mesenchymal transition (EMT).
EMT is the process by which epithelial cells lose cell polarity, cell to cell
adhesion, and gain migratory and invasive properties.(123) These cells transform into
mesenchymal stem cells (Figure 17). EMT is essential for numerous development
processes, and plays a role in wound healing, fibrosis, and cancer. EMT was recognized
as a feature of embryogenesis, and its reverse process, mesenchymal-epithelial transition
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Figure 16. Genomic Location of miR-200 Family and Seed Sequence of Functional
Groups 1 and 2.

miR-200a, miR-200b and miR-429 located on Chromosome 1
miR-200c and miR-141 located on Chromosome 12
Red = Functional group 1, Blue = Functional group 2. The two functional groups only
differ in the seed sequence by one nucleotide, U for Group 1 and C for Group 2.

Jurmeister S, Uhlmann S, Sahin Ö. MIR200C (microRNA 200c). Atlas Genet Cytogenet
Oncol Haematol. 2012;16(2):92-99
49

Figure 17. Epithelial to Mesenchymal Transition

Epithelial to Mesenchymal Cell Transition – loss of cell adhesion leads to constriction
and extrusion of newly mesenchymal cell.

Thiery JP, Sleeman JP. (2006). "Complex networks orchestrate epithelial-mesenchymal
transitions". Nature Reviews Molecular Cell Biology 7: 131–142
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(MET), is critical for development of many tissues and organs in the developing embryo.
Epithelial cells are stationary, expressing high levels of E-cadherin, whereas
mesenchymal cells are able to migrate and invade and express N-cadherin, fibronectin,
and vimentin. The loss of E-cadherin is considered a fundamental event in EMT, either
direct or indirect. Direct loss occurs when Zinc finger E-box-binding homeobox (ZEB) 1
/ ZEB2 binds to E-cadherin and causes repression of transcription. Several signaling
pathways may induce EMT. TGF-β activates the expression of ZEB and SNAIL to
regulate EMT in cancer. The p53 tumor suppressor inhibits EMT by activating the
expression of various miRNAs. EMT is involved in cancer progression and metastasis.
The loss of E-cadherin causes cells to lose adhesion which break through the basement
membrane, increasing the invasive properties of cells.
Differential expression of the miR-200 family is involved in initiation and
progression of malignant transformation. The miR-200 family regulates epithelial to
mesenchymal transition by targeting ZEB1 and ZEB2.(124) Low miR-200 levels were
identified in breast cancer cells that underwent EMT in response to TGF-β, conversely,
increased miR-200 expression prevented TGF- β induced EMT. Induction of EMT
occurred with inhibition of the miR-200 family and subsequent upregulation of ZEB1 and
ZEB2. Hence, it was concluded that downregulation of the miR-200 family was an
important step in tumor progression. Another study identified miR-200 members were
downregulated in colorectal adenocarcinomas that had invaded beyond the basement
membrane, however; lymph node metastases showed high expression of miR-200. On the
other hand, colorectal adenomas and adenocarcinomas with intact basement membranes
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had high expression of miR-200 members. Their conclusions supported the involvement
of the miR-200 family in EMT and cancer progression.(125)
Significant work has been performed investigating the role of the miR-200 family
in many processes. The miR-200 family has been implicated in cell transformation and
tumorigenesis, cancer metastasis, tumor growth, angiogenesis, invasion and migration,
tumor cell survival in circulation, intra and extravasation, and as a potential diagnostic
and prognostic tool.(126) The majority of research with the miR-200 family focuses on
EMT of cancer cells where dysregulation is considered to exhibit tumor suppressive
behavior by blocking EMT. However; increased levels of miR-200c, in particular, in
various cancers contradicts the tumor suppressive role of this miRNA.(127) miR-200
family levels are enriched in epithelial tissues. This is supported by lower expression of
miR-200c in metastatic colorectal cancer cell lines, SW620, LOVO, and RKO compared
to epithelial colorectal cancer cell lines, SW480, HT-29, and T84.(128-130) Multiple
studies have also confirmed the findings of enhanced levels of miR-200c in CRC tissue
compared to healthy control tissue.(131-133) Overexpression of miR-200c induced cell
proliferation in SW620 CRC cell lines (129), whereas another study observed reduced
proliferation in SW480 and SW620 CRC cell lines.(130) Downregulation of miR-200c in
HT-29 and T84 CRC cell lines increased cell apoptosis and decreased tumor
growth.(134)
Since the data regarding the miR-200 family is contradictory more work is needed
to gain a better understanding on the role this family plays in cancer, and to understand
the mechanisms involved in cancer initiation and progression. Much of what we already
know relates to the individual miRNAs, miR-200b and miR-200c, hence more research
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needs to be conducted on the remaining members, miR-200a, miR-141, and miR-429. It
is important to be able to distinguish which miR-200 family members act as tumor
suppressors and which may promote cancer progression.
e)

Ras Associated Domain-Containing Protein (RASSF2)
The Ras family of onco-proteins regulates a wide range of biological processes by

interacting with a variety of effector proteins, the most well characterized being BRAF
and PI3K. Activated forms of Ras are associated with oncogenesis usually due to
mutation, however; they can also exhibit growth-antagonistic effects such as senescence,
cell cycle arrest, differentiation, and apoptosis.(135, 136) Previously, a novel Ras
effector, RASSF1, was identified as a mediator of apoptosis and cell cycle arrest, with the
protein displaying many properties associated with tumor suppressors.(137) Ras
Associated Domain-Containing Protein (RASSF2) is one of ten in the RASSF family of
proteins encoded by RASSF genes 1-10, and subsequent to the discovery of RASSF1,
was identified as a novel K-Ras specific effector and tumor suppressor.(138) RASSF2
was found to be a negative regulator of Ras, by binding directly to K-Ras in a GTPdependent manner via the Ras effector domain. The interaction of RASSF2 and Ras
proteins was found to be specific to K-Ras, rather than H-Ras or N-Ras. RASSF2 was
found to promote apoptosis and cell-cycle arrest, and was frequently downregulated in
human lung cancer cell lines. In addition, overexpression of RASSF2 inhibited growth of
lung cancer cells suggesting that RASSF2 shared the properties, similar to other
identified RASSF proteins, in being a potential tumor suppressor. Other groups
confirmed the findings that RASSF2 and K-Ras form an endogenous complex, and
demonstrated tumor suppressor properties by the loss of expression causing enhanced cell
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proliferation and invasion in cell lines.(139) RASSF2 is silenced by aberrant DNA
promoter methylation in CRC, and expression has been found to be frequently
downregulated in CRC cell lines. This is supported by studies investigating the properties
and methylation status of RASSF2 in CRC tissue and colorectal adenoma samples.
Multiple studies have reported the methylation of RASSF2 between 42% - 73% in CRC
samples, and one study reported the methylation status of RASSF2 of 100% in colorectal
adenoma samples.(140-142)
It is widely accepted that RASSF members belong to a recently identified family
of tumor suppressor Ras effectors for which epigenetic silencing by promoter
methylation has been shown to occur throughout the progression of cancer including
CRC.(143-145) Clarification of cellular mechanisms that regulate the signaling pathways
RASSFs are involved in is further needed, however; RASSFs may have the potential to
be developed as a molecular biomarker or targeted therapy for CRC.
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CHAPTER V
HYPOTHESIS, SPECIFIC AIMS, AND EXPERIMENTAL PLAN

a)

Key Objective
To investigate the role of the miR-200 family on the tumor suppressor RASSF2,

and determine the effect it has on activity within the mitogen-activated protein kinase
(MAPK) signaling pathway, in a normal colon epithelial (CCD 841) cell line and a
Dukes’ C (HT-29) colorectal cancer cell line.
b)

Hypothesis
The MAPK pathway is a major regulator of cell proliferation and is frequently

mutated in CRC. miRNAs from the miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141, miR-429) have been shown to promote cell proliferation when transfected into
various cell lines. It has been shown that the miR-200 family targets RASSF2, a negative
regulator of K-Ras, however; the relationship between miR-200, RASSF2, K-Ras, and
subsequent activity within the MAPK pathway in colorectal cancer, has not yet been fully
described.
We hypothesize that miR-200 family expression differs between normal colon
epithelial (CCD 841) and Dukes’ C (HT-29) colorectal cancer cells and manipulation of
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their expression could modify cancer cell behavior. In doing so, the miR-200 family may
have the potential to be developed as a therapeutic intervention in CRC (Figure 18).
c)

Specific Aims
1: To determine the expression of the miR-200 family and RASSF2 in both a
normal colon epithelial (CCD 841) and a sporadic Dukes’ C (HT-29) colorectal
cancer cell line.
2: To examine the gain and loss of function of the miR-200 family and the
resulting effect on RASSF2 expression, in both a normal colon epithelial (CCD
841) and a sporadic Dukes’ C (HT-29) colorectal cancer cell line, respectively.
3: To demonstrate the effect of the miR-200 family on MAPK signaling pathway
activity as measured by activation of pathway proteins and resulting cell
proliferation.

d)

Experimental Plan
The overall goal of this project is to investigate the role of the miR-200 family in

relation to activity of the MAPK signaling pathway and effect upon cell proliferation
mediated via the tumor suppressor RASSF2. We will first evaluate expression of the
miR-200 family in a normal colon epithelial (CCD 841) cell line and compare it to the
expression in Dukes’ stage CRC cell lines. If a difference is observed, RASSF2, a target
of the miR-200 family, will be investigated, along with the associated signaling pathway.
Secondly, the miR-200 family will be manipulated using miRNA mimics and antagomirs
to increase or decrease their expression in the respective cell lines, and RASSF2 mRNA
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and protein expression then measured. Finally, MAPK signaling pathway activation will
be assessed and cell proliferation, the major resulting functional outcome, will be
measured in both normal colon epithelial and Dukes’ C CRC cells. We will thus
determine whether manipulation of the miR-200 family can influence CRC cell behavior
and thereby investigate the potential use of the miR-200 family as a therapeutic target in
CRC.

57

Figure 18. Hypothesis Overview.
miR-200 Family and Normal Colon Epithelium (CCD 841)

58
miR-200 Family and Dukes’ C (HT-29) Colorectal Cancer

CHAPTER VI
MATERIALS AND METHODS

a.

Cell Lines
For the purposes of this study, five cell lines representing the four stages of

modified Dukes’ A to D colorectal cancer and normal colon epithelium were acquired
from American Type Culture Collection (ATCC®, Manassas, Virginia). Sporadic
colorectal cancer cell lines were selected for study. KRAS mutation and microsatellite
instability status is shown in Table 7. Cells were cryopreserved in liquid nitrogen at 80˚C until being initiated and allowed to grow for future testing. All cell lines were
adherent in nature, cultured in cell culture flasks and incubated at 37˚C and 5% CO2.
Cells were grown to 70-90% confluence before being harvested for further studies.
1. CCD 841 CoN (ATCC® CRL-1790™)
Normal epithelial colon cells harvested from a human female fetus at 21 weeks
gestation period, and cultured in Eagle’s Minimum Essential Medium (EMEM)
with 15% fetal bovine serum (FBS), and supplemented with a 0.5% mixture of
penicillin, streptomycin, amphotericin B, and 0.5% L-glutamine (Figure 19).
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2. SW1116 (ATCC® CCL-233™)
Dukes’ A, grade III, primary colorectal adenocarcinoma epithelial cells were
harvested from a 73 year-old man. Cells were cultured in Dulbecco’s Modified
Eagle (DMEM) medium with 10% FBS, and supplemented with a 0.5% mixture
of penicillin, streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line
was microsatellite stable and positive for expression of mutated K-Ras oncogene
(Figure 20).
3. SW480 (ATCC® CCL-228™)
Dukes’ B, primary colorectal adenocarcinoma epithelial cells were harvested from
a 50 year-old man. Cells were cultured in Dulbecco’s Modified Eagle (DMEM)
medium with 10% FBS, and supplemented with a 0.5% mixture of penicillin,
streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line was
microsatellite stable and positive for expression of K-Ras oncogene with a
mutation in codon 12 of the ras oncogene (Figure 21).
4. HT-29 (ATCC® HTB-38™)
Dukes’ C, primary colorectal adenocarcinoma epithelial cells were harvested from
a 44 year-old woman. The cells were cultured in McCoy’s 5A medium with 10%
FBS, and supplemented with a 0.5% mixture of penicillin, streptomycin,
amphotericin B, and 0.5% L-glutamine. This cell line was microsatellite stable
and positive for expression of wild type K-Ras oncogene (Figure 22).
5. T84 (ATCC® CCL-248™)
Dukes’ D, secondary colorectal adenocarcinoma epithelial cells derived from a
metastatic lung site were harvested from a 72 year-old man. The cells were
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cultured in Dulbecco’s Modified Eagle’s medium and Ham’s F-12 (DMEM/F-12)
with 10% FBS, and supplemented with a 0.5% mixture of penicillin,
streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line was
microsatellite stable and positive for expression of mutated K-Ras oncogene
(Figure 23).
b.

Maintenance of Cell Lines
All cell lines were incubated at 37˚C and 5% CO2 until being transferred to a

sterile cell culture hood for subsequent use. Gloved hands were cleansed with 70%
ethanol (EtOH) prior to handling and transferring cell culture flasks from the incubator to
the hood. All other items transferred into the culture hood were cleansed with 70% EtOH
prior to use. Once cells were returned to the incubator, the cell culture hood was cleansed
with 70% EtOH to maintain sterility. Only one cell line at a time was used in the culture
hood to avoid cross contamination.
1. Establishment of Cell Lines from Cryopreservation
Cell line specific medium was removed from refrigeration and warmed to room
temperature in a water bath. For each cell line, 8mL of culture medium was added to a
15mL tube. Another 8mLs of culture medium was then added to a 25cm3 flask. Care was
taken not to wet the flask neck in order to avoid contamination. The cell line name,
medium, %FBS, passage number of cells, date and initials were written on each flask.
Each cryopreserved cell line vial was removed from liquid nitrogen and immediately
thawed in a 37˚C water bath. The O-ring and cap were suspended above the water to
avoid contamination. Once thawed, the contents were transferred to the 15mL tube using
a 1000μL pipette. This tube was centrifuged at 830 rpm, at 37˚C for 7 minutes, until a
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cell pellet was formed. The medium was then aspirated and discarded and the cell pellet
re-suspended with 1mL culture medium. This re-suspended cell mixture was then
transferred to the labelled 25cm3 culture flask. Cells were visualized within the culture
flask under a microscope before transferring to the incubator for growth.

2. Sub-culturing and Splitting of Cells
Cells were visualized daily under a microscope (10X) to monitor growth. Once
the cells were deemed to be 70 – 90% confluent they were divided. Appropriate culture
medium and a 6mL aliquot of trypsin-ethylenediaminetetraacetic acid (EDTA) were
warmed and thawed, respectively, in a water-bath to room temperature before being
cleansed with 70% EtOH and placed in the culture hood. The medium was decanted into
a waste beaker and 6mL of trypsin was added to the flask and was gently rocked back
and forth before being placed back into the incubator for 5 minutes to aid trypsinization.
During this time, 18mL of the appropriate cell line culture medium was added to a new
75cm3 flask(s). After 5 minutes, cells were removed from the incubator and observed
under an inverted microscope in order to confirm that the cells were no longer adhered to
the bottom of the flask. Once this was confirmed, the flask was returned to the culture
hood and 9mL culture medium was added to the flask to stop trypsinization and multiple
washings performed to ensure cell collection. Following this, the cell suspension was
transferred to a new 15mL tube and centrifuged at 830rpm for 7 minutes. The supernatant
was discarded and the remaining cell pellet was re-suspended in 1mL medium using a
micropipette tip to achieve single-cell suspension. An additional 4mL medium was then
added and thoroughly mixed to dilute the cells.
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Table 7. Characteristics of Cell Lines
MAPK Pathway
Cell Line
CCD 841
Normal Colon
Epithelium
SW1116
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Dukes’ A
CRC
SW480
Dukes’ B
CRC
HT-29
Dukes’ C
CRC
T84
Dukes’ D
CRC
*

Site of Origin

Subcultivation Ratio*

MSI Status
KRAS

BRAF

ERBB3

Colon

-

-

-

-

1:2 – 1:3

Colon

Stable

Mutated

WT

WT

1:3 – 1:6

Colon

Stable

Mutated

WT

WT

1:2 – 1:8

Distal Colon

Stable

WT

Mutated

WT

1:3 – 1:8

Stable

Mutated

WT

WT

1:2 – 1:4

Lung
Metastasis

Subcultivation refers to the multiple passes or generations of each cell line

Medium (%FBS)

EMEM (15)

DMEM 1X (10)

DMEM 1X (10)

McCoy’s 5A (10)

DMEM/F-12 (10)

Figure 19. Morphology and Growth of Cell Lines CCD 841 CoN – Normal Colon Epithelium
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The CCD 841 cells are epithelial-like cells that grow as a flattened and disorganized layer in culture. Cells are long and epitheliallike with long thin processes. At low density cells will be relatively sparse and at higher densities cells may begin to overlap one
another.

CCD 841 CoN (ATCC® CRL-1790™) is available at: www.atcc.org

Figure 20. Morphology and Growth of Cell Lines SW1116 – Dukes’ A CRC
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At low density, SW1116 cells can be seen briefly as single, unclumped cells. At higher density, cells appear to grow together in
clumps.

SW1116 (ATCC® CCL-233™) is available at: www.atcc.org

Figure 21. Morphology and Growth of Cell Lines SW480 – Dukes’ B CRC
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At lower densities, cells will appear more rounded and may appear in small clumps of a few cells. At high densities, the cells will take
on a more polygonal shape with defined borders between cells.

SW480 (ATCC® CCL-228™) is available at: www.atcc.org

Figure 22. Morphology and Growth of Cell Lines HT-29 – Dukes’ C CRC
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The cells attach in patches as three-dimensional aggregates and as they divide and grow they flatten into an epithelial cell monolayer.
At lower densities, cells will attach as single cells and will be spread apart. Cells appear rounded. At higher densities, many
independent "islands" of growing cells come together leading to the large cell mass seen in the higher density picture
HT-29 (ATCC® HTB-38™) is available at: www.atcc.org

Figure 23. Morphology and Growth of Cell Lines T84 – Dukes’ D CRC
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Similar to HT-29. At lower densities, small islands of cells will be growing sparsely around the flask. At higher densities, these cell
"islands" will join together to form the large cell mass seen in the high density picture
T84 (ATCC® CCL-248™) is available at: www.atcc.org

Cell counting was performed manually and cells stained with tryphan blue using a
1:5 dilution by diluting 10μL of the cell solution to 40μL before sampling a 10μL aliquot
for counting using a hemocytometer. Total cell count was determined by the following
formula:
Cell Count x Dilution Factor x 104 x Volume
Following this, cells were either plated at pre-determined amounts for use in experiments
or sub-cultivated to allow for further growth.
3. Freezing of Cells
Cells were split and counted as described above. Cells selected for
cryopreservation were at low passage numbers (<10) and viable. Cryo-media was created
using a solution of the cells respective media and dimethylsulfoxide (DMSO) so that the
final volume contained 5% DMSO. Cells were then added to the solution so that the
concentration of cells was 4 x 106 cells/2mL of cryo-media. 2mL of this suspension was
labeled and stored in a sterile cryogenic vial (Corning Inc.). These cryogenic vials were
then stored in a Cryo 1°C Freezing Container (NALGENE) ethanol bath and placed in a 80°C storage freezer in order to achieve a -1°C/min cooling rate. After 24 hours of
cooling in the ethanol bath, these cryogenic vials were transferred to a liquid nitrogen
storage container for storage until needed.
c.

Harvesting Cells for RNA
Cells were plated at 250,000 cells/2mL in a 6-well plate and allowed to grow to

confluence. Once confluent, the medium was carefully removed from each well and
discarded. 300μL of cell lysis buffer was added to each well. After 5 minutes, the bottom
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of each well was scraped using a pipette tip and the resulting product was collected in
labelled freeze tubes and stored at -80˚C until needed.
d.

Harvesting Cells for Protein
Cells were plated at 250,000 cells/2mL in a 6-well plate and allowed to grow to

confluence. For every 6-well plate, 1μL of protease and 1μL of phosphatase inhibitors
were supplemented to 1mL of radio immune-precipitation assay (RIPA) buffer. The
medium was carefully removed from each well and 150μL of RIPA / protease &
phosphatase mix was added. The bottom of each well was scraped using the rubber
plunger from a syringe, the sample was collected and stored at -80˚C in pre-labeled
freeze tubes or immediately processed for protein quantification.
e.

Total RNA Isolation
Isolation of total RNA from cell lysates was performed using the Ambion®

miRVana miRNA Isolation Kit (Life Technologies, Carlsbad, CA). A 1:10 concentration
of homogenate was added to each cell sample and incubated on ice for 10 minutes. Equal
volumes of Acid-Phenol-Chloroform were added to the lysate. Samples were vortexed
and centrifuged for 5 minutes at 10,000g. Careful removal of the aqueous top phase to a
new tube was then performed to avoid contamination and maintain purity. The total
volume removed was recorded and 1.25 times 100% EtOH was added to the lysate. After
mixing, 700μL sample was added to a new spin column. This was centrifuged for 15
seconds at 10,000g and flow-through was discarded. 700μL of Wash Solution 1 was
added to each spin column, followed by centrifugation at 10,000g for 10 seconds before
the flow-through was discarded. This was followed by the addition of 500μL of Wash
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Solution 2 and centrifugation at 10,000g for 10 seconds. The same procedure is then
performed for Wash Solution 3. The spin column is removed and the sample placed into a
new tube, which is then centrifuged for 1 minute at 10,000g to remove excess liquid.
Finally, 40μL of pre-heated elution solution (95˚C) was added to the filter in the spin
column and centrifuged for 30 seconds at maximum speed. Quantitation of total RNA
quantity and quality was then determined using a Nanodrop 2000 spectrophotometer
(ThermoFisher Scientific®, Middlesex, MA). Samples can be contaminated with other
molecules, such as proteins or organic compounds. To assess the nucleic acid quality of
our samples we measure the ratio of absorbance at 260nm and at 280nm (A260/280). For
good quality RNA, the A260/280 should be ~1.8-2.2. The total RNA concentration and
quality of our samples are shown in Tables 8 & 9.
f.

microRNA Screening of Cell Lines
For each cell line, the expression levels of 384 miRNAs were examined using

TaqMan® Low Density Array (TLDA) human miRNA card A following the
manufacturers protocol (Life Technologies, Carlsbad, CA). Each cell line was screened
for expression of dysregulated miRNA four times.
Complementary DNA (cDNA) was generated from total RNA samples using the
TaqMan® miRNA Reverse Transcription kit (Life Technologies, Carlsbad, CA). Reverse
transcription (RT) total reaction volume for each sample was 75μL, consisting of 45μL
master mix and 30μL RNA (4000ng) sample. The RT master mix volume per sample was
as follows:
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Table 8. Total RNA Concentration and Purity of Normal Colon Epithelial and Dukes’ Colorectal Cancer Cell Lysates used for miRNA
Cell Line Screening.

RNA Concentration (ng/μL)

RNA Purity (A260/280)

Replicate (no.)

Replicate (no.)

Cell Line

2

3

4

1

2

3

4

Normal Colon Epithelium CCD 841

137

147

42

34

2.08

2.04

2.02

2.09

Dukes’ A CRC (SW1116)

108

451

-

-

2.06

2.18

-

-

Dukes’ B CRC (SW480)

247

649

-

-

2.08

2.11

-

-

Dukes’ C CRC (HT-29)

496

356

-

-

2.11

2.09

-

-

Dukes’ D CRC (T84)

507

497

-

-

2.10

2.10

-

-
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Table 9. Total RNA Concentration and Purity following Transfection with miR-200 Family Mimics and Antagomirs.
RNA Concentration (ng/μL)

RNA Purity (A260/280)

Replicate (no.)

Replicate (no.)

Cell Line

Normal
Colon
Epithelium
(CCD 841)

miR-200
family
Antagomirs

Dukes’ C
CRC
(HT-29)
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miR-200
family
Mimics

miR-200a
miR-200b
miR-200c
miR-141
miR-429
miR-200 All*
M-†
miR-200a
miR-200b
miR-200c
miR-141
miR-429
miR-200 All*
A-††

1

2

3

4

5

1

2

3

4

5

147
128
132
185
105
181
100
156
66
158
202
144
288
214

176
99
189
212
153
92
80
133
141
116
148
94
194
182

161
263
130
149
193
148
140
146
130
138
148
190
198
192

263
184
256
90
132
175
127
134
82
98
204
174
257
198

126
167
83
192
344
210
94
114
121
123
183
211
294
103

1.79
1.76
1.80
1.76
1.88
1.73
1.93
2.05
2.00
2.00
2.10
2.04
2.09
2.08

1.79
1.71
1.72
1.77
1.68
1.73
1.95
2.11
2.11
2.07
2.04
2.03
2.08
2.07

1.75
1.76
1.77
1.72
1.71
1.84
1.80
2.08
2.02
2.10
2.02
2.04
2.07
2.09

1.79
1.71
1.76
1.99
1.69
1.70
1.83
2.11
2.10
2.08
2.06
2.04
2.08
2.09

1.76
1.71
1.97
1.74
1.83
1.70
1.71
2.07
2.10
2.10
2.06
2.09
2.09
2.05

*

Combination of all five miRNA mimics or antagomirs together (125pmol total vs. 25pmol for each individual miRNA)

†

Mimic Negative Control

††

Antagomir Negative Control

Volume (μL) per 75μL Reaction†

Component
Megaplex™ Reverse Transcription Human Pool

9.00

A v.2.1 Primers
100nM dNTPs (with dTTP)

2.25

MultiScribe™ Reverse Transcriptase, 50U/μL

16.88

10X Reverse Transcription Buffer

9.00

25mM MgCl2 Solution

10.20

RNase Inhibitor, 20U/ μL

1.12

Total

48.45

†

Inclusive of 12.5% excess to compensate for pipetting loss

Once complete, the sample was vortexed, centrifuged to remove air bubbles and run on a
pre-set thermal cycler program. Samples were either used immediately or stored at -20˚C
until further use.
Each TLDA card comprises of 8 fill reservoirs with a fill port on the left and a
vent port on the right. For each sample, a master mix of 900μL was prepared in a 1.5mL
microcentrifuge tube, vortexed and centrifuged to eliminate air bubbles. The master mix
consisted of the following:
Volume (μL) per TLDA Card†

Component
TaqMan® Universal Master Mix II, no

450

UNG
Nuclease-free water

375

Product from RT reaction

75
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Total
†

900

Inclusive of 12.5% excess to compensate for pipetting loss

The TaqMan Array card was removed from its packaging and warmed to room
temperature with minimal exposure to sunlight and placed on a lab bench, with the foil
side down. Each reservoir was filled with 100μL of sample-specific PCR mix made from
a single cDNA sample. The micropipette was held at an angled position to dispense the
sample and care was taken not to displace the reaction mix outside of the reservoir or
introduce air bubbles. After the reservoir had been filled with PCR reaction mix, the card
was centrifuged using a Sorvall® centrifuge bucket and holder for 1 minute at 1200rpm.
Confirmation that filling of the TaqMan card was complete was observed by a consistent
reduction in the fluid within each reservoir. The TaqMan Array card was sealed using a
TaqMan® Array Micro Fluidic Card Sealer, removed and quantitative real-time
polymerase chain reaction (qRT-PCR) performed using a ViiA™ 7 Real-Time PCR
System (ThermoFisher Scientific®, Middlesex, MA).
Expression levels of each individual miRNA were normalized to RNU6
(endogenous internal reference gene), using a cycle threshold (Ct) of 0.2, in order to
calculate ΔCt values for analysis using the comparative ΔCt method. miRNA expression
of each CRC cell line was compared to the miRNA expression of the normal colon
epithelium cell line.
g.

microRNA Single Assay Validation
For miRNA single assay quantification, total RNA was converted to cDNA using

the TaqMan® miRNA Reverse Transcription kit and specific TaqMan® miRNA primers
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for the miR-200 family and RNU6 (Life Technologies, Carlsbad, CA). Specific
TaqMan® probes for each miRNA were then used to bind to complementary sequences
on target cDNA during qRT-PCR (Life Technologies, Carlsbad, CA). Reverse
transcription (RT) total reaction volume for each sample was 15μL, consisting of 7μL
master mix, 3μL TaqMan® miRNA primer, and 5μL RNA (2ng/μL) sample. The RT
master mix was made using the following:
Volume (μL) per 15μL reaction†

Component
100nM dNTPs (with dTTP)

0.17

MultiScribe™ Reverse Transcriptase, 50U/μL

1.13

10X Reverse Transcription Buffer

1.69

RNase Inhibitor, 20U/ μL

0.21

Nuclease-free water

4.68

TaqMan® miRNA primer

3.38

Total

11.25

†

Inclusive of 12.5% excess to compensate for pipetting loss

Once the master mix for each miRNA was made, the contents were gently mixed and
centrifuged to bring the solution to the bottom of the tube, and then placed on ice until the
RT reaction was ready to be run. 10μL of each RT master mix was added to wells in a
96-well reaction plate followed by 5μL of RNA sample. The reaction plate was then
sealed, vortexed, and centrifuged before running on a pre-set thermal cycler program.
Once complete, the cDNA was either used immediately to run qRT-PCR or stored at 20˚C until further use.
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Nucleic acid quantification was performed using a Step-One Plus qRT-PCR
system (Life Technologies, Carlsbad, CA). A 10μL qRT-PCR reaction volume was
performed and each reaction was performed in duplicate. Similar to the RT reaction, a
master mix cocktail for qRT-PCR for each miRNA was made as follows:
Volume (μL) per 10-μL
Component

reaction†

TaqMan® MicroRNA Assay (20X)

0.56

TaqMan® Universal Master Mix II, no UNG

5.63

Nuclease-free water

3.57

Product from RT reaction (Minimum 1:15 Dilution)

1.33

Total

11.08

†

Inclusive of 12.5% excess to compensate for pipetting loss
Once made, the master mix was gently mixed and centrifuged to bring solution to

the bottom of the tube. 8.67μL PCR master mix was dispensed into each well on a 96well plate followed by 1.33μL of the RT product. Once loaded, the plate was sealed,
vortexed and centrifuged to spin down the contents and eliminate air bubbles. The
reaction plate was then run on a pre-set thermal cycler program using the Step-One Plus
qRT-PCR machine.
The levels of each individual miR-200 family member were normalized to RNU6,
using a Ct threshold of 0.1, in order to calculate ΔCt values for analysis using the
comparative ΔCt method. All reactions were completed in duplicate. Analysis was

77

performed for expression of individual miR-200 family members for each CRC cell line
as compared to that seen in the normal colon epithelium cell line.
h.

messengerRNA (mRNA) Quantification
For mRNA quantification, total RNA was converted to cDNA using a High

Capacity cDNA Reverse Transcription kit (Life Technologies, Carlsbad, CA) with
random nucleotide primers. Preparation of a 2X RT master mix per 20μL reaction was
made as follows:
Volume (μL) per 20-μL reaction

Component
10X RT Buffer

2.00

25X dNTP Mix (100mM)

0.80

10X RT Random Primers

2.00

MultiScribe™ Reverse Transcriptase

1.00

RNase Inhibitor

1.00

Nuclease-free water

3.20

Total

10.00

10μL of the 2X RT master mix was pipetted into each well of a 96-well reaction
plate followed by 10μL of RNA sample (2ng/μL) and mixed. The plate was sealed,
vortexed and centrifuged to spin down the contents and eliminate air bubbles. The plate
was placed on ice until ready to load into and run the thermal cycler on a pre-set program.
On completion, the cDNA RT plate was either used immediately to run qRT-PCR or
stored at -20˚C until further use.
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Specific TaqMan® probes for RASSF2 and 18S (endogenous internal reference
gene) were used during qRT-PCR and all reactions were completed in duplicate. The
total number of PCR reactions was determined and the reaction mix was made as follows:
Component

Volume (μL) per reaction

TaqMan® Fast Advanced Master Mix (2X)

5.00

TaqMan® Gene Expression Assay (20X)

0.50

Nuclease-free water

3.50

Total

9.00

Nine μL PCR reaction mix and 1μL cDNA was added to each well, mixed, and
covered with optical adhesive film and sealed. The plate was briefly centrifuged to spin
down the contents and eliminate air bubbles. Nucleic acid quantification was performed
using a Step-One Plus qRT-PCR system (Life Technologies, Carlsbad, CA). The
expression levels of RASSF2 mRNA were normalized to 18S, using a Ct threshold of
0.1, in order to calculate ΔCt values for analysis using the comparative ΔCt method.
Analysis was performed between the Dukes’ C (HT-29) CRC cell line as compared to the
normal colon epithelium (CCD 841) cell line.
i.

microRNA Transfection
Transfection experiments were conducted in two cell lines; CCD 841 (normal

colon epithelium) and HT-29 (Dukes’ C CRC). Each cell line was transfected with each
individual member of the miR-200 family, all five members of the family combined, and
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scrambled oligonucleotides as a negative control, using mirVana™ miRNA mimics (for
CCD 841) and antagomirs (for HT-29) (Life Technologies, Carlsbad, CA).
For our experiments, the concentration of the cell suspension was determined and
cells plated into individual wells depending on the type of experiment being performed
(Table 10). Once plated, cells were allowed a 24-hour acclimation period to adhere to the
plate prior to transfection. After 24 hours when cells were 60-80% confluent in each well
they were transfected using Lipofectamine® RNAiMAX transfection reagent (Life
Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Firstly, miRNA
(10μM) was diluted in Opti-MEM® Medium, followed by dilution of Lipofectamine®
RNAiMAX Reagent in Opti-MEM® Medium. The diluted miRNA and Lipofectamine®
were then combined in a 1:1 ratio and incubated at room temperature for five minutes.
The miRNA-lipid complex was then added to each well. Incubation of the cells at 37˚C
was performed for 24 hours after transfection prior to cell harvesting and further analysis.
Cell samples were stored in labelled tubes and stored at -80 ˚C until further use.
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Table 10. Transfection Protocol Procedure Details.
Final
Lipofectamine®
RNAiMAX Per
Well (μL)

miRNA-Lipid
Complex Per
Well (μL)
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Experiment

Plate Format

Cell Concentration

Final Transfection
miRNA Per Well
(pmol)

miRNA mRNA qRTPCR

6-well

250,000/2mL

25

7.5

250

RASSF2 and K-Ras
Protein Quantification

6-well

250,000/2mL

25

7.5

250

Cell Proliferation

12-well

0.5 – 1 x 105/mL

5

1.5

50

ERK1/2
Total/Phosphorylated
ELISA Assay

6-well

250,000/2mL

25

7.5

250

j.

Protein Quantification
Cell samples were removed from storage and thawed over ice. Two 1.5mL freeze

tubes per sample were labelled with the cell line, date and miRNA clearly visible. The
freeze tubes underwent sonication with two pulses per sample and were returned to ice.
The sonicator was wiped with kimwipes between each sample and the process was
repeated. Once complete, the samples were transferred into a 1.5mL tube and then
centrifuged at 10,000rpm for ten minutes in order to pellet the debris. The upper layer of
pure protein was transferred into a new 1.5mL labelled tube.
1. Preparation of the protein standards
Protein concentration was determined using the bicinchoninic acid (BCA) assay
and performed in a 96-well plate. Protein standards were prepared in a serial 2-fold
dilution down the plate. To begin, 20μL of double distilled water was pipetted into the
wells of rows B-H in the first two columns on the plate. In the first two columns of row
A, 40μL of BCA standard was added. Transferal of 20μL of BCA standard from well A
to B was performed and mixed well. A further 20μL from mixed well B was transferred
to well C. This process was repeated until row G. The remaining row H contained only
20μL of double distilled water. The resulting total volume in each well was 20μL.
2. Preparation of the protein samples (1:20 dilution)
Depending on the number of samples to be quantitated, 38μL of double distilled
water was added to wells in the odd numbered columns from the third column onwards.
Two microliters of protein sample was then added to each corresponding well and mixed
thoroughly to make a total volume of 40μL. From each mixed water/protein sample,
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20μL was transferred to the adjacent well. To read the amount of protein in each sample,
equal amounts of Pierce™ BCA Protein Assay Reagent A and B (Thermo Scientific,
Rockford, IL) were combined before 160μL was added to every well used, covered and
incubated at 37˚C for 30 minutes. The 96-well plate was then read using a
SPECTRAmax® PLUS 384 microplate spectrophotometer at a wavelength of 540nm.
k.

Western Blot
Western blots (n=5 for each protein) were performed for target proteins in the

MAPK pathway (Table 11). Cell samples were prepared to contain a standardized
amount of 40μg/μL of protein. Bolt® (4X) lithium dodecyl sulfate sample buffer was
added to each sample, vortexed and heated for 10 minutes at 90˚C. A 10-well Bolt™ 8%
Bis-Tris Plus Gel was placed in a Bolt® Mini Gel Tank which was then filled half-way
with NuPAGE® MOPS SDS running buffer. Wells were loaded with 8μL molecular
marker standards and 30μL protein sample. The remainder of the tank was then filled
with running buffer. Gels were run at 165mV for 45 minutes in order to identify the
proteins of interest. Once complete, the gel was transferred over 10 minutes onto a
nitrocellulose membrane using the iBlot® Gel Transfer Device. The nitrocellulose
membrane was then cut between the protein of interest and the endogenous internal
reference, β-actin (MW 42kDa). The membrane was then blocked for β-actin in 5% milk
or 5% Bovine Serum Albumin (BSA) in Tris-buffered saline and Tween 20 (TBS-T) for
the protein of interest for 1 hour at room temperature on an orbital shaker. During the
hour, primary antibodies for target proteins were made according to the manufacturer’s
instructions. Primary antibodies were poured over the membranes and incubated
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Table 11. MAPK Pathway Proteins of Interest with Molecular Weight and Primary and
Secondary Antibody Dilutions

Protein

Observed Molecular
Weight (kDa)

Primary
Antibody Dilution

Secondary
Antibody Dilution

RASSF2

37

1:1000

1:1000

K-Ras

21

1:250

1:1000

β-Actin
(Internal
Reference)

42

1:10000

1:1000
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overnight at room temperature while being mixed. After three 5 minute washings with
TBS-T, each membrane was submersed with horseradish-peroxidase-conjugated
secondary antibody and mixed at room temperature for 1 hour. The membrane was again
washed three times for 5 minutes each with TBS-T, incubated in equal parts of Enhanced
Chemiluminescence (ECL) Reagents A and B for 5 minutes in the dark in order to detect
the target protein, and then developed and imaged using a ChemiDoc MP imager
(BioRad, Hercules, CA).
l. Cell Proliferation
For cell proliferation studies, cells were grown in flasks until ready for use. Cells
were split as previously described (pg.62) and cell concentration determined. HT-29 cells
and CCD841 were plated in duplicate at a concentration of 100,000 cells/mL and 50,000
cells/mL in individual wells in 12-well plates, respectively. Cells were left for 24 hours to
adhere to the plate before being serum starved. For this, the medium from each well was
removed and replaced using medium with a 0.5% FBS concentration. After 2 hours, this
was removed and replaced with the normal growth medium and cells were then
transfected with the respective antagomirs and mimics as previously described (pg.7980). Transfection was stopped after 24 hours, cells were trypsinized and once the cells
were confirmed no longer adherent to the bottom of the plate, the trypsinization process
was stopped. A 10μL sample from each well was inserted into a dual chamber counting
slide (Bio-Rad, Hercules, CA) and cell number was measured each day for 5 days using
an automated cell counter (TC20™ Bio-Rad, Hercules, CA).
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m.

Enzyme-Linked Immunosorbent Assay (ELISA)
Total and phosphorylated ERK1/2 was measured using the InstantOne™ ELISA

96 Well (Affymetrix, Santa Clara, CA). Cell sample lysates were prepared from grown
cells that had been plated and transfected in 6-well plates as previously described (pg.7980). Sample preparation of adherent cultured cells was prepared by removing media from
the cells, and 300μL of pre-prepared cell lysis mix (1X) was added to each well. The
plate was shaken at room temperature for 5 minutes. Each well was scraped with a pipette
tip and the samples were collected in labeled tubes and stored at -80˚C until further use.
Protein concentration was determined using the BCA assay previously described to
ensure protein concentration was in the range of at least 0.1-0.5mg/mL in order to be
detected.
When ready for use, cell lysates were thawed over ice and the desired number of
InstantOne™ microplate strips needed for the experiment, including the positive control
lysate and negative control, were determined. Unused microplate well strips were
returned to the storage pouch and sealed until next use. Fifty μL of the positive and
negative controls, and cell sample lysates to be tested were added to each of the assay
wells. In addition, 50μL of prepared antibody cocktail mix was added to each well; the
plate sealed and then incubated for 1 hour at room temperature on a microplate shaker at
300rpm. Following incubation, the wells were washed three times with 200μL wash
buffer (1X) /well and on completion any remaining wash solution was removed by
inverting the plate on a paper towel. To this, 100μL of a detection reagent was added to
each well and incubated for 30 minutes at room temperature with shaking at 300rpm.
After 30 minutes, the reaction was stopped by adding 100μL stop solution to each well.
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The plate was read by measuring the absorbance of the samples using the
SPECTRAmax® PLUS 384 microplate spectrophotometer at a wavelength of 450nm.
n.

Statistical methods and analytic techniques
1. Where possible, for each cell line and transfected miRNA, samples were prepared

in replicates of five, unless stated. Cell culture samples were grown from new freezes and
transfected at the same passage to maintain a true sample size of five. All reactions were
run in duplicate and the averages of the duplicates used for analysis. Once obtained, all
data was analyzed and graphs were prepared in GraphPad Prism v6.01 (GraphPad
Software, Inc. La Jolla, CA). Data was tested for normality, and where confirmed,
comparison of two data sets was conducted using an unpaired two-tailed Student’s t test.
Statistical significance was defined as p<0.05 and data presented as mean ± standard
deviation.
A t test was chosen as the most appropriate method for statistical analysis as we
were performing comparisons between two groups for each experiment. If three or more
groups (i.e. multiple cell lines) were being compared, analysis using ANOVA would
have been performed. Sample size was justified at n=5, based on the preliminary cell line
screening and validation of single miRNA expression. At a power of 80%, and adjusted
α=0.05, if we were to detect a difference in mean miRNA expression between Dukes’ C
CRC and normal colon epithelial cells of 1000 fold, a sample size of n=2 would be
sufficient to detect a significant difference in miRNA expression between cell lines. We
chose to perform experiments with n=5, to permit detection of smaller differences in
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mean miRNA expression and other variables such as amount of protein, mRNA, and
proliferation, and to keep all experimental replicates consistent.
2. qRT-PCR
Raw fluorescence data (Ct values) generated by the Step-One Plus qRT-PCR
instrument (Life Technologies, Carlsbad, CA) were exported for analysis using the
comparative ΔΔCt method. The data was visualized on an amplification curve, and the
threshold bar was set at 0.1. The value for the threshold bar was determined as it was
consistently above the background noise, was within the exponential phase and was
below the plateau and linear phases of the amplification curve. Where the threshold bar
cut the amplification curve a Ct value was derived from the x-axis. All undetermined
values were replaced with a Ct value of 40. The Ct value of each miRNA and mRNA was
normalized to an endogenous control (RNU6 for miRNA and 18S for mRNA) generating
a ΔCt. The ΔΔCt was calculated by the following;
ΔCt

=

Ct(target case)

-

Ct(reference case)

ΔCt

=

Ct(target control)

-

Ct(reference control)

ΔΔCt =

ΔCt(case)

-

ΔCt(control)

The resulting normalized gene expression level was calculated by 2(-ΔΔCt), representing
the fold change between samples.
3. Western Blot
The chemiluminescent blots were imaged first with the ChemiDoc MP imager
(BioRad, Hercules, CA). The Band Analysis tools of ImageLab software version 5.2.1
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(BioRad, Hercules, CA) were used to select and determine the background-subtracted
density of the bands. Normalization was performed by dividing the relative density units
of the protein of interest by the relative density units of the endogenous control, β-actin.
The ratios obtained from this were analyzed as described above by averaging the ratios of
each replicate for each sample and comparing the sample of interest against the negative
control.
4. ELISA Assay
Each sample replicate was run in duplicate and analyzed using the
spectrophotometer at 450nm. Results were adjusted against the negative control (blank)
and the absorbance units for each sample were averaged. A ratio of phosphorylated to
total ERK 1/2 was calculated for each sample and a comparison of the ratios between
each transfected miRNA sample and its corresponding negative control was performed.
5. Cell Proliferation
Total cell numbers for each sample were obtained and averages of the duplicates
were taken. For each of the five days, a comparison between total cell numbers of each
transfected miRNA sample compared to the negative control was performed. Statistical
analysis was conducted as described above.

89

CHAPTER VII
COLORECTAL CANCER CELL LINE EXPRESSION OF RASSF2 mRNA AND
PROTEIN

a)

Introduction
We have previously identified increased expression of all members of the miR-

200 family in colorectal cancer compared to normal colon epithelium cell lines (pg. 36).
The members of the miR-200 family are highly enriched in epithelial tissues and they
have been linked to several cancers including CRC.(146) Using the results of our
screening data, pathway analysis software identified all members of the miR-200 family
to have a validated regulatory role upstream of Ras proteins in MAPK canonical pathway
(pg. 45). Further analysis of the miR-200 family confirmed validated target interaction
with Ras associated domain-containing protein 2 (RASSF2) (pg. 47). RASSF2 is one of
six proteins in the RASSF family that in humans is encoded by the RASSF2 gene.
RASSF2 is a negative regulator of Ras and binds directly to K-Ras within the Ras
effector domain in a GTP-dependent process.(138) RASSF2 has previously been shown
to promote apoptosis, cause cell cycle arrest and is regarded as a novel K-Ras-specific
effector and potential tumor suppressor. Therefore, we hypothesize that RASSF2
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expression will differ between CRC cell lines and a normal colon epithelial (CCD 841)
cell line.
b)

Results
1. RASSF2 mRNA Expression in Colorectal Cell Lines
RASSF2 mRNA expression was present in normal colon epithelial cell line

samples across all replicates. Conversely, RASSF2 mRNA expression was lower or
absent in each Dukes’ Stage CRC cell line. Dukes’ A (SW1116) and C (HT-29) CRC cell
lines had no expression of RASSF2 mRNA, as determined by Ct values ≥40, whereas
Dukes’ B (SW480) CRC had lower expression and Dukes’ D (T84) CRC cell lines had
partial expression of RASSF2 mRNA, respectively. A representative qRT-PCR
amplification plot of RASSF2 mRNA expression for all colorectal cell lines is shown in
figure 24. Average Ct values (± standard deviation) representing relative expression of
RASSF2 mRNA along with the internal control, 18S, are shown in table 12.
Comparison of expression of RASSF2 mRNA between each Dukes’ Stage CRC
and the normal colon epithelial cell line showed significant downregulation in all Dukes’
Stage CRC cell lines. RASSF2 mRNA was downregulated with a fold regulation between
-80 and -6828. Of all the CRC cell lines, Dukes’ C (HT-29) stage CRC had the largest
downregulation of RASSF2 mRNA -6828 compared to the normal colon epithelial (CCD
841) cell line (Figure 25).
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2. RASSF2 Protein Expression in Colorectal Cell Lines
The genes in DNA encode protein molecules which are required to carry out all
functions necessary for life. Expressing a gene means manufacturing its corresponding
protein. Initially, DNA is transferred to mRNA by a process called transcription. The
resulting mRNA is a single-stranded copy of the gene, which then undergoes translation
into a protein molecule. We have ascertained downregulation of RASSF2 mRNA in
colorectal cancer cell lines compared to normal colon epithelium, the next step in the
process to see whether this downregulation translated to the expression of RASSF2
protein.
We observed the presence of RASSF2 protein in all normal colon epithelium
(CCD 841) cell line samples, with a RASSF2/β-actin ratio of 0.014. No RASSF2 protein
was detected in Dukes’ A (SW1116), C (HT-29) or D (T84) CRC samples, whereas
Dukes’ B (SW480) CRC had a RASSF2/β-actin ratio of 0.016. Western blot results for
all cell lines are shown in figure 26. There was a significant downregulation of RASSF2
protein in Dukes’ A (SW1116), C (HT-29) and D (T84) CRC cell lines compared to the
normal colon epithelial (CCD 841) cell line (p<0.05), whereas there was no difference in
RASSF2 protein expression observed between the Dukes’ B (SW480) CRC cell line and
the normal colon epithelium (CCD 841) cell line (p 0.99).
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Figure 24. RASSF2 mRNA Expression in All Colorectal Cell Lines
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RASSF2 mRNA expression in Colorectal Cell Lines. Downregulation of RASSF2 mRNA was observed in all CRC cell lines compared
to the normal colon epithelium cell line.

Table 12. Average Cycle Threshold and ΔΔCt Values, and Fold Regulation for Expression of RASSF2 mRNA in All Colorectal Cell
Lines

Average Ct Values (+/- sd)
Colorectal Cell Line

Average ΔΔCt Values (+/- sd)

Fold Regulation
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RASSF2

18S

Dukes’ A CRC
SW1116

40.0 (+/- 0.0)

12.0 (+/- 0.1)

12.0 (+/- 0.1)

-4174

Dukes’ B CRC
SW480

33.9 (+/- 0.4)

11.6 (+/- 0.3)

6.3 (+/- 0.6)

-80

Dukes’ C CRC
HT-29

40.0 (+/- 0.0)

11.3 (+/- 0.1)

12.7 (+/- 0.1)

-6828

Dukes’ D CRC
T84

39.5 (+/- 0.5)

11.5 (+/- 0.2)

12.0 (+/- 0.5)

-4229

Normal Colon
Epithelium
CCD 841

27.4 (+/- 0.2)

11.5 (+/- 0.2)

-

-

Figure 25. RASSF2 mRNA Expression in Colorectal Cancer Cell Lines Compared to a
Normal Colon Epithelial (CCD 841) Cell Line.
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c)

Discussion
We found that there is a decreased expression of RASSF2 mRNA and protein in

Dukes’ A (SW1116), C (HT-29) and D (T84) colorectal cancer cell lines compared to the
normal colon epithelial (CCD 841) cell line, in keeping with previously reported studies.
Multiple studies have identified RASSF2 to have properties and behavior of a
tumor suppressor gene. RASSF2 is a negative effector of Ras protein and it is inactivated
by promoter hypermethylation in many cancers. Frequent downregulation of RASSF2
has been detected in colorectal, gastric, lung, ovarian, cervical, and thyroid cancers; to
name a few. Our results suggest that RASSF2 is implicated in colorectal carcinogenesis
due to the significant difference observed in expression between normal colon epithelial
and colorectal cancer cell lines.
Previous studies have identified association with methylation status of RASSF2
and colorectal cancers and adenomas. RASSF2 methylation has frequently been observed
in colorectal cancers and adenomas. One study reported RASSF2 methylation to be
present in approximately 40% of all CRC and colorectal adenoma samples tested.(142) In
addition to this, methylation of RASSF2 was significantly associated with KRAS and or
BRAF mutations. Another more recent study showed that RASSF2 methylation was
positively correlated with KRAS mutation in MSS, but not MSI, CRC.(140) Interestingly
another study observed methylation of RASSF2 to be negatively associated with KRAS
mutation in sporadic CRC. In this study, 75% of CRC specimens with RASSF2
methylation had no mutation of KRAS.(141) Methylation of RASSF2 was observed in
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Figure 26. Western Blot Showing Expression of RASSF2 Protein in Normal Colon Epithelium (CCD 841) and Dukes’ Colorectal
Cancer Cell Lines.
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Presence of RASSF2 protein in normal colon epithelium and Dukes’ B colorectal cancer cell lines. Significant downregulation of
RASSF2 protein in Dukes’ A (SW1116), C (HT-29) and D (T84) colorectal cancer cell lines compared to normal colon epithelium
(p<0.05)

almost 90% of all colorectal adenoma samples, suggesting that RASSF2 methylation is
an early event in CRC. Another series observed concomitant KRAS and BRAF mutations
in 73% of colorectal adenoma samples suggesting that the epigenetic changes occur
simultaneously and may work synergistically.(147)
The CRC cell lines used in this study have differing KRAS and BRAF mutation
status. We specifically chose to investigate MSS sporadic CRC cell lines. Of the four cell
lines, only Dukes’ C (HT-29) CRC was KRAS wild type with BRAF mutation. The
remaining three all had mutations of KRAS. It is possible that RASSF2 expression was
present in the Dukes’ B (SW480) CRC cell line due to fact that not all CRC will have
methylation of RASSF2 as previously described. If RASSF2 is not methylated, then
inactivation will not occur and it is likely that CRC develops due to other genetic
abnormalities and aberrant signaling events.
Observing absent or downregulation of RASSF2 in colorectal cancer cell lines
compared to a normal colon epithelial (CCD 841) cell line provides us with a platform in
which to investigate the development of CRC. RASSF2 behaves as a Ras effector and
functions as a tumor suppressor, therefore; if we are able to alter the expression of
RASSF2 we may be able to change cell behavior by modulating Ras/Raf/MEK/ERK
activation.
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CHAPTER VIII
GAIN OF FUNCTION OF miR-200 FAMILY IN A NORMAL COLON EPITHELIAL
(CCD 841) CELL LINE

a)

Introduction
We have seen that miR-200 family levels are decreased and RASSF2 mRNA and

protein levels are present in a normal colon epithelial (CCD 841) cell line compared to
the Dukes’ C (HT-29) CRC cell line. The purpose of the next series of experiments was
to confirm the proposed oncogenic action of the miR-200 family members and the
inhibitory effect they have on RASSF2 mRNA and subsequent RASSF2 protein
expression.
Gain of function experiments with miRNA mimics are used to augment the
function of endogenous miRNA for easier detection of a phenotypic change. In the case
of the normal colon epithelium (CCD 841) cell line, endogenous levels of miR-200
family members were low. Transfecting with miRNA mimics to supplement miR-200
family function would therefore decrease the expression of the target gene RASSF2, and
subsequent presentation of the phenotype.
From our previous knowledge, miRNA-200 family members all target RASSF2.
RASSF2 is a negative regulator of K-Ras. Therefore; we hypothesized that increased
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expression of miR-200 family members, would cause RASSF2 mRNA and protein levels
to decrease in normal colon epithelial cells
b)

Results
1. Overexpression of miR-200 family members in the normal colon epithelial (CCD
841) cell line
Transfection of miR-200a, miR-200b, miR-200c, miR-141, and miR-429 mimics

into normal colon epithelial cells was successful (Figure 27). Increased expression of
each individual miR-200 family member was achieved when compared to the negative
control transfection (M-). For all members of the miR-200 family, miRNA mimics
achieved from 1084 to 5638 fold increase in the respective miRNAs (p<0.001) (Figure
28).
We also performed an experiment evaluating the additive effect of combining all
five miR-200 family members into the same transfected wells, in an attempt to replicate
what occurs in the natural environment. Transfection of the five miRNA mimics in
combination increased expression of every miR-200 family member, as measured by
qRT-PCR, compared to the negative control (Figure 29).
2. Effect of Overexpression of miR-200 Family Members on RASSF2 mRNA
Manipulation of miR-200 expression led to changes in RASSF2 mRNA
expression (Figure 30). miR-200a, miR-200b, miR-200c, and the combination of all five
miR-200 family members were associated with decreased RASSF2 mRNA expression.
miR-200b significantly downregulated RASSF2 mRNA with a fold regulation of -1.74
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(p 0.016). There was no change in RASSF2 mRNA expression in the normal colon
epithelial (CCD 841) cell line transfected with miR-141 and miR-429 (p 0.5 and 0.6,
respectively) (Figure 31).
3. Effect of Overexpression of miR-200 Family Members on RASSF2 Protein
Following transfection with miR-200 family member mimics, we observed a
decrease in the relative expression of RASSF2 protein in the normal colon epithelial
(CCD 841) cell line. RASSF2 protein levels were significantly lower in cells when
transfected with miR-200a, miR-200b, miR-429, and the combination of all five miR-200
family members (p<0.05) (Figures 32 & 33).
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Figure 27. miR-200 Family Members Amplification Plot Following Transfection
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Amplification plot showing increased expression (denoted by the lower cycle number) of all miR-200 family mimics in the normal
colon epithelial (CCD 841) cell line compared to the negative control.

Figure 28. miR-200 Family Expression in a Normal Colon Epithelial (CCD 841) Cell
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Transfection with individual miR-200 family miRNA mimics led to significant over
expression of each individual miR-200 family member 24 hours after transfection of a
normal colon epithelial (CCD 841) cell line. Data shown are mean ± standard deviation.
* indicates p<0.001 vs. negative control.
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Figure 29. miR-200 Family Expression in a Normal Colon Epithelium (CCD 841) Cell
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Transfection with the combination of all miR-200 family miRNA mimics led to a
significant increase in expression of miR-200a, miR-200b, miR-200c, and miR-429 after
24 hours. Data shown are mean * indicates p<0. 001 vs. negative control (M-).
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Figure 30. RASSF2 mRNA Amplification Plot Following Transfection of Normal Colon Epithelial (CCD 841) Cell Line with miR200b.

105
Significant downregulation of RASSF2 mRNA was observed in the normal colon epithelial (CCD 841) cell line transfected with miR200b after 24 hours. This can be observed by the later expression (higher cycle number) of RASSF2 compared to the negative control.

Figure 31. RASSF2 mRNA Expression in a Normal Colon Epithelial (CCD 841) Cell
Line Following Transfection with miR-200 Family Mimics.
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Transfection with miR-200a, miR-200b, miR-200c, and the combination of all five miR200 family members led to decreased RASSF2 mRNA expression. Data shown are mean ±
standard deviation. * indicates p<0.05 vs. negative control (M-).
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c)

Discussion
miRNA mimics provide a means to study the function of specific miRNAs in a

range of organisms, and to validate their role in regulating target genes. miRNA mimics
are small, chemically modified double-stranded RNA molecules that are designed to
mimic endogenous mature miRNAs, resulting in artificial down-regulation of target
mRNA translation. Our results demonstrate the ability to successfully transfect and
increase the expression of the miR-200 family. We have seen an increase in each
individual miR-200 family member when transfected into normal colon epithelial cells,
which in turn has led to a decreased expression of RASSF2 mRNA and protein levels
compared to the negative control. Of importance to note, following transfection with
miR-200 family mimics, the largest increase in fold change was observed with miR-200b.
This corresponded with the largest downregulation of RASSF2 mRNA and subsequent
protein expression, consistent with the idea that the higher the fold change observed, the
more likely a response in down-regulation of the target mRNA.
We also were successful in transfection of all five miR-200 family members in
combination. By adding each miR-200 family mimic to cultured wells and measuring
each individual expression, we observed much higher upregulation of miRNA expression
than when transfected alone. This also resulted in the largest down-regulation of RASSF2
protein expression.
It is worth noting the use of miRNA mimics and interpreting results with caution.
It has recently been reported that it remains unclear as to whether transient transfection of
miRNAs behave similarly to endogenous miRNAs. Transient transfection of miRNA
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Figure 32. Western Blot of RASSF2 Protein in Normal Colon Epithelial Cell Line when Transfected with miR-200 Family Mimics.
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Transfection of miR-200a, miR-200b, miR-429, and a combination of all five miR-200 family mimics led to a significant decrease in
RASSF2protein level compared to the negative control.

Figure 33. RASSF2 Protein Expression in a Normal Colon Epithelial (CCD 841) Cell
Line Following Transfection with miR-200 Family Mimics. The Results Show the Ratio
of RASSF2 Protein Relative to β-Actin, Expressed as Relative Density Units (RDu), for
each miRNA compared to the Negative Control (M-).

R A S S F 2 /  - a c tin ( R D u )

0 .0 8

0 .0 6

0 .0 4

*
*

*

*

0 .0 2

0 .0 0
200a 200b 200c

141
m iR N A

429

A ll

MM e a n  s .d
* p < 0 .0 5
n=5

Decreased expression of RASSF2 protein was observed in a normal colon epithelial
(CCD 841) cell line following transfection with miR-200a, miR-200b, miR-429, and the
combination of all miR-200 family members. Data shown are mean ± standard deviation.
* indicates p<0. 05 vs. negative control (M-).
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mimics at high concentrations in HeLa cells caused non-specific alterations in gene
expression, while at low concentrations achieved expression levels comparable to other
methods, such as lentiviral infection or plasmid transfection, but failed to efficiently
suppress target gene expression. (148) We performed transfection at 24 and 48 hours and
at 48 hours saw inconsistency within miRNA expression of the negative control. This led
us to believe that transfection after 48 hours was inadequate and the results could not be
appropriately interpreted, hence a transfection time of 24 hours was implemented. To
minimize the risk of over expressing miRNA levels beyond normal pathological levels,
we followed the manufacturer’s recommendations. For each individual miR-200 family
member a 25pmol transfection concentration was used, up to a maximum total of
125pmol when combining all five miR-200 family members together. These
concentrations were within the limits of transfection described by Jin et al.
In conclusion we have managed to demonstrate significant upregulation of the
miR-200 family in normal colon epithelial cells in contrast to the relatively low or absent
baseline expression. This has in turn led to a decrease in RASSF2 mRNA expression
consistent with the hypothesis that miR-200 family members target RASSF2. By
demonstrating reduced RASSF2 protein expression we are now able to examine the
effects of increasing the expression of the miR-200 family and its role within activity of
the MAPK signaling pathway in colorectal cancer.
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CHAPTER IX
LOSS OF FUNCTION OF miR-200 FAMILY IN DUKES’ C (HT-29) COLORECTAL
CANCER CELL LINE

a)

Introduction
Dukes’ C (HT-29) CRC cell line was chosen for investigation over other cell lines

for three reasons,


it had consistently higher expression of each individual miR-200 family member
on initial screening compared to the other three CRC cell lines. We believed that
in order to reduce expression of miRNAs using miRNA antagomirs, a cell line
with higher expression of the miRNAs to be investigated would provide the best
opportunity to detect downregulation.



the HT-29 Dukes’ C CRC cell line is microsatellite stable, within the MAPK
pathway it is KRAS is wild type and is not mutated like the other CRC cell lines
we screened.



it is a metastatic cell line (derived from a cancer with lymph node metastasis) and
therefore observations made on it would have direct clinical relevance and
applicability with respect to designing newer treatment modalities.
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miRNA antagomirs suppress the function of endogenous miRNAs. They prevent
miRNAs from binding to its desired mRNA binding site, thus increasing its target gene
expression. In previous experiments we have observed miR-200 family members to be
highly expressed in the Dukes’ C (HT-29) CRC cell line. We have also seen that
increasing the expression of miR-200 family members in a normal colon epithelial (CCD
841) cell line reduces the expression of RASSF2 mRNA and RASSF2 protein.
The purpose of these experiments is to determine whether the reverse process is
true in a CRC cell line. We therefore; hypothesized that by decreasing expression levels
of miR-200 family members we would expect to see increased expression of RASSF2
mRNA and subsequent RASSF2 protein expression.
b)

Results
1. Inhibition of miR-200 family members in the Dukes’ C (HT-29) CRC cell line
Transfection of miR-200 family antagomirs to reduce expression of each miRNA

was confirmed by qRT-PCR. Downregulation was observed in three of these miRNAs,
significantly for cells transfected with miR-200b and miR-200c antagomirs with a fold
downregulation of -2.8 and -10.6, respectively (p<0.01) (Figure 34). When transfection of
all five miR-200 family members in combination was performed, there was significant
downregulation of miR-200a, miR-200b, miR-200c, and miR-429 (p<0.01) (Figure 35).
2. Effect of Inhibition of miR-200 Family Members on RASSF2 mRNA
In our preliminary cell line screening, we did not identify RASSF2 mRNA
expression in the Dukes’ C (HT-29) CRC cell line. By knocking down expression of the
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miR-200 family, we observed an increase in RASSF2 mRNA expression in this Dukes’ C
(HT-29) CRC cell line, significantly for miR-429 (p<0.001) Transfection of all five miR200 family members in combination, significantly up-regulated RASSF2 mRNA
expression 3.7 fold (p<0.01) (Figure 36).
3. Effect of Inhibition of miR-200 Family Members on RASSF2 Protein
In our preliminary cell line studies, we did not detect the presence of RASSF2
protein in the Dukes’ C (HT-29) CRC cell line. Transfection with miR-200 family
antagomirs demonstrated expression of RASSF2 protein in all samples, as detected by
Western blot (Figure 37). Significant up-regulation of RASSF2 protein was observed in
the Dukes’ C (HT-29) CRC cell line transfected with miR-141, miR-429, and all five
miR-200 family members in combination, compared to the negative control (A-) (p<
0.05) (Figure 38).
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Figure 34. miR-200 Family Expression in a Dukes’ C (HT-29) Cell Line Following
Transfection with Individual miR-200 Family Antagomirs.
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Transfection with miR-200 family miRNA antagomirs led to a significant decrease in
expression of miR-200b and miR-200c after 24 hours. Data shown are mean ± standard
deviation. * indicates p<0. 01 vs. negative control (A-).
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Figure 35. miR-200 Family Expression in a Dukes’ C (HT-29) CRC Cell Line Following
Transfection with All miR-200 Family Antagomirs in Combination.
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Figure 36. RASSF2 mRNA Expression in a Dukes’ C (HT-29) CRC Cell Line Following
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control (A-).
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c)

Discussion
Following transfection of a Dukes’ C (HT-29) CRC cell line with miR-200 family

antagomirs we observed down-regulation of individual miR-200 family members up to
10 fold. miRNA inhibitors are chemically modified, single-stranded oligonucleotides
designed to specifically bind to and inhibit endogenous miRNAs, resulting in artificial
up-regulation of target mRNA translation. The binding of the antagomir with the target
miRNA leads to the degradation of the miRNA by the same process as described for
short interfering RNAs.(149)
We demonstrated significant down-regulation of miR-200b and miR-200c in a
Dukes’ C (HT-29) CRC cell line and upregulation of RASSF2 mRNA when transfecting
cells with each individual miR-200 family antagomir. Although not a significant finding,
we believed the more important observation of miR-200 family inhibition would manifest
at the protein level.
In untransfected Dukes’ C (HT-29) CRC cell lines, there was absent expression of
both RASSF2 mRNA and protein. The fact we were able to observe amplification of
RASSF2 at any level was encouraging. Again, transfection of all five miR-200 family
members in combination produced the most significant RASSF2 mRNA expression.
It is possible that transient transfection could affect miRNA silencing and
ultimately the results we observe. Anecdotally, inhibition of miRNA using miRNA
antagomirs is less successful than miRNA mimics. A number of factors can influence the
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Figure 37. Western Blot of RASSF2 Protein in Dukes’ C (HT-29) CRC Cell Line Following Transfection with miR-200 Family
Antagomirs.
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Knockdown of miR-200 family members led to an increase in RASSF2protein level compared to the negative control (A-).

Figure 38. RASSF2 Protein Expression in a Dukes’ C (HT-29) CRC Cell Line Following
Transfection with miR-200 Family Antagomirs. The Results Show the Ratio of RASSF2
Protein Relative to β-Actin, Expressed as Relative Density Units (RDu), for each miRNA
compared to the Negative Control (A-).
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Increased expression of RASSF2 protein was observed in the Dukes’ C (HT-29) CRC cell
line following transfection with miR-141, miR-429, and the combination of all miR-200
family members. Data shown are mean ± standard deviation. * indicates p<0. 05 vs.
negative control (A-).
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amount to which expression of a target gene is reduced, such as, transfection efficiency,
transcription rate of the gene of interest, mRNA and protein stability, and the growth
characteristics of the particular cell line used.(150) In our experience, Dukes’ C (HT-29)
CRC cells are very quick to divide and grow and this may be a factor in the limited
success of miRNA antagomir transfection as accelerated growth may outweigh the
supply. Lipofectamine RNAiMAX used in our experiments has been developed to
increase the transfection efficiency of RNA into in vitro cell cultures. Lipofectamine
reagent contains lipid subunits that can form liposomes in an aqueous environment,
which entraps the transfection agent, in this case miRNA antagomirs. It is a cationic
liposome formulation which joins with negatively charged nucleic acid molecules
allowing them to overcome the electrostatic repulsion of the cell membrane.(151, 152)
Fusion with the negatively charged plasma membrane occurs allowing the nucleic acid to
cross into the cytoplasm. The contents are available to the cell for replication or
expression, however; the nucleic acid must reach the cell nucleus to begin transcription.
Issues could arise, for example, if the material never reaches the nucleus in the first place,
or if it becomes trapped in the reassembling nuclear envelope following mitosis.(150)
Another consideration would be to perform multiple transfections. This would
enable newly grown cells to take up the lipid complex and miRNA antagomir. However,
transfection-mediated cytotoxicity can be an issue and can mask the true phenotype of the
target gene being studied and also affect cell viability. Increasing the frequency of
transfection was not considered to be a viable option in our experiments, as we have
already demonstrated that a greater than 24 hour transfection was detrimental to cell
function and that interpretation of the results at 48 hours was unreliable.
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In conclusion, we have demonstrated the ability to down-regulate expression of
members of the miR-200 family which were highly expressed in Dukes’ C (HT-29) CRC
cells. In doing so, we have upregulated expression of RASSF2 mRNA and protein. This
suggests that inhibition of miR-200 family members increases RASSF2 expression. This
warrants further investigation on the effect of inhibition of the miR-200 family and
subsequent RASSF2 expression on KRAS and MAPK pathway activity.
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CHAPTER X
MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY ACTIVATION AND CELL
PROLIFERATION

a)

Introduction
In our previous experiments we demonstrated that successful overexpression of

the miR-200 family in a normal colon epithelial (CCD 841) cell line leads to reduced
expression of RASSF2 mRNA and RASSF2 protein. Conversely, knockdown of the miR200 family members in a Dukes’ C (HT-29) CRC cell line leads to an increased
expression of RASSF2 mRNA and RASSF2 protein. RASSF2 is a known negative
regulator of Ras and binds directly to K-Ras, within the MAPK pathway, in a GTPdependent manner. Once K-Ras is activated, it initiates a phosphorylation cascade of
downstream proteins resulting in altered gene expression. miRNAs from the miR-200
family have been shown to promote cell proliferation when transfected into various cell
lines and may impact K-Ras expression and downstream pathways.(153) As the miR-200
family target RASSF2, and considering that RASSF2 is a negative regulator of K-Ras,
manipulation of miR-200 family expression may lead to changes within the MAPK
pathway affecting transcription factors and the resulting downstream functional processes
such as cell proliferation (Figure 39).
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Figure 39. Association between RASSF2 and K-Ras in the MAPK Pathway.

X

RASSF2 is a negative regulator of Ras. It binds directly to K-Ras in a GTP-dependent
manner via the Ras effector domain. The miR-200 family target RASSF2 and changes in
expression could affect transcription factors and the resulting downstream functional
processes such as cell proliferation.
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We propose that by manipulating the expression of the miR-200 family members
in a normal colon epithelial (CCD 841) and a Dukes’ C (HT-29) CRC cell line we will
affect total K-Ras expression thereby leading to a change in activity within the MAPK
pathway, as measured by the phosphorylation of ERK 1/2, a downstream protein within
this pathway. We also hypothesize that increased activation of ERK 1/2 in a normal colon
epithelial (CCD 841) cell line will result in increased cell proliferation, suggesting
oncogenic-like properties, whereas decreased ERK 1/2 activation in a Dukes’ C (HT-29)
CRC cell line will result in decreased cell proliferation, highlighting the potential use of
miR-200 family as a therapeutic target in CRC.
b)

Results
Total K-Ras Expression
Following successful transfection of a normal colon epithelial (CCD 841) cell line

with miR-200 family members we observed an increase in total K-Ras expression in cells
transfected with miR-200a, miR-141 and miR-429 compared to the negative control (M-)
(p< 0.05) (Figures 40 & 41).
In a Dukes’ C (HT-29) CRC cell line total K-Ras was increased compared to the
negative control (A-) following transfection with miR-200a and miR-200c (p< 0.05)
(Figures 42 & 43).
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ERK 1/2 Activation
In a normal colon epithelial (CCD 841) cell line, measurement of total and
phosphorylated ERK 1/2 was performed following transfection with miR-200 family
mimics. We observed an increased ratio of phosphorylated to total ERK 1/2 compared to
the negative control (M-). This indicates a significant activation of the MAPK pathway
for all miR-200 family mimics (p < 0.01) (Figures 44 & 45).
In the Dukes’ C (HT-29) CRC cell line, measurement of total and phosphorylated
ERK 1/2 following transfection with miR-200 family antagomirs, showed a decreased
ratio of phosphorylated to total ERK 1/2 compared to the negative control (A-) indicating
a significant decrease in MAPK pathway activation for cells transfected with miR-200a,
miR-200b, miR-141, and the combination of all five miR-200 family member antagomirs
(p < 0.05) (Figures 46 & 47).

.
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Figure 40.Western Blots for Total K-Ras Protein Expression in a Normal Colon
Epithelial (CCD 841) Cell Line.

Representative Western blot images showing total K-Ras expression. Bands were
detected at 21kDa in all cells transfected with miR-200 family mimics.
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Figure 41. Total K-Ras Protein Expression in a Normal Colon Epithelial (CCD 841) Cell
Line Following Transfection with miR-200 Family Mimics.
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An increase in total K-Ras expression was observed in cells transfected with miR-200a,
miR-141 and miR-429 compared to the negative control (M-). Data shown are mean ±
standard deviation. * indicates p<0. 05 vs. negative control (M-).
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Figure 42. Western Blots for Total K-Ras Protein Expression in a Dukes’ C (HT-29)
CRC Cell Line.

Representative Western blot images showing total K-Ras expression. Bands were
detected at 21kDa in all cells transfected with miR-200 family antagomirs.
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Figure 43. Total K-Ras Protein Expression in a Dukes’ C (HT-29) CRC Cell Line
Following Transfection with miR-200 Family Antagomirs.
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An increase in total K-Ras expression was observed in cells transfected with miR-200a,
and miR-200c compared to the negative control (A-). Data shown are mean ± standard
deviation. * indicates p<0. 05 vs. negative control (A-).
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Cell Proliferation
Measuring cell proliferation as the resulting functional outcome of activity within
the MAPK pathway was performed for both normal colon epithelial (CCD 841) and
Dukes’ C (HT-29) CRC cell lines. Following transfection of miR-200 family mimics in
the normal colon epithelial (CCD 841) cell line, we observed a significant increase in cell
proliferation at day five in cells transfected with miR-200a, miR-200c and miR-141
mimics compared to the negative control (p < 0.05) (Figure 48). Cell proliferation was
also increased in the normal colon epithelial (CCD 841) cell line following transfection
with miR-200a at days 2, 4 and 5 (p < 0.01).
No significant increase in cell proliferation was observed for miR-200b, miR-429,
and when all five miR-200 family members were transfected into cells in combination.
Cell proliferation growth curves for each miR-200 family member are shown in figure
49.
In the Dukes’ C (HT-29) CRC cell line, cell proliferation was significantly
decreased following transfection for individual (p < 0.001) and the combination of all
miR-200 family member antagomirs (p < 0.05) at day five compared to the negative
control (Figure 50). miRNAs-200b, miR-200c, miR-141, miR-429, and the combination
of all five miR-200 family members had a significant decrease in cell proliferation at day
four (p < 0.05). Cell proliferation growth curves for each miR-200 family member are
shown in figure 51.
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Figure 44. ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Normal Colon
Epithelial (CCD 841) Cell Line Following Transfection with miR-200 Family Mimics.

Data shown are mean ± standard deviation.
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Figure 45. ERK 1/2 Activation in a Normal Colon Epithelial (CCD 841) Cell Line
Following Transfection with miR-200 Family Mimics.
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control (M-).
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Figure 46. ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Dukes’ C
(HT-29) CRC Cell Line Following Transfection with miR-200 Family Antagomirs.

Data shown are mean ± standard deviation.
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Figure 47. ERK 1/2 Activation in a Dukes’ C (HT-29) CRC Cell Line Following
Transfection with miR-200 Family Antagomirs.
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c)

Discussion
We have demonstrated that overexpression of miR-200 family members and a

reduction in RASSF2 protein expression leads to increased K-Ras expression in normal
colon epithelial (CCD 841) cells transfected with miR-200a, miR-200b, miR-141, and
miR-429 mimics. In addition, greater expression of miR-200 family members also
increases activation of the MAPK signaling pathway as demonstrated by enhanced
phosphorylation of ERK 1/2 in relation to total levels (Figure 39). This increase in
activity may also explain the observed increase in cell proliferation as a measure of a
functional outcome of the increased MAPK pathway activity.
Conversely, loss of function of miR-200a and miR-200c in Dukes’ C (HT-29)
CRC cells results in increased K-Ras expression, confirming previous findings that miR200c is inversely correlated with K-Ras expression in certain cancers. (154) Despite the
increase in K-Ras expression, we observed a decreased ratio of phosphorylated to total
ERK 1/2 associated with loss of function in miR-200a, miR-200b, and miR-141,
indicating MAPK pathway inactivation. MAPK pathway inactivation may explain the
significant decrease in cell proliferation seen for all members of the miR-200 family.
The ERK MAPK signaling pathway is regarded as one of the most important
regulators of cell proliferation.(155) There is growing evidence to suggest that activation
within this pathway is involved in the pathogenesis, progression, and oncogenic behavior
of colorectal cancer.(52) Disruption of the cell cycle in CRC is common and contributes
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Figure 48. Cell Proliferation in a Normal Colon Epithelial (CCD 841) Cell Line
Following Transfection with miR-200 Family Mimics.

Cell count as a measurement of proliferation shows statistically significant increase in
count by day 5 for miR-200a, miR-200c, and miR-141 mimics.
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Figure 49. Cell proliferation growth curves for each miR-200 family member in a Normal Colon Epithelial (CCD 841) Cell Line.
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Figure 50. Cell Proliferation in a Dukes’ C (HT-29) CRC Cell Line Following
Transfection with miR-200 Family Antagomirs.

Cell count as a measurement of proliferation shows statistically significant decrease in
count by day 5 for all miR-200 family antagomirs.
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Figure 51. Cell proliferation growth curves for each miR-200 family member in a Dukes’ C (HT-29) CRC Cell Line.
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to tumorigenesis. Changes in ERK signaling may contribute to cell cycle arrest in the
G2/M phase.(156) Ras activity is another observation suggestive of MAPK pathway
activation. High Ras activity is accompanied by an increased ERK 1/2 activity.(157) We
have demonstrated higher K-Ras expression following transfection with miR-200 family
mimics and antagomirs. Whilst we might expect to see lower levels of K-Ras in Dukes’ C
(HT-29) CRC cell lines transfected with miR-200 family antagomirs, hence reducing
downstream ERK 1/2 activity, we saw an increase in total K-Ras levels compared to the
negative control. Although miRNAs are typically associated with decreased protein
expression, a possible explanation could be differential activation of K-Ras expression
and repression of translation through separate base-pairing mechanisms. In addition,
although we cannot make a direct comparison between the normal colon epithelial (CCD
841) cell lines, transfected with miR-200 family mimics, compared to the Dukes’ C (HT29) CRC cell lines, transfected with miR-200 family antagomirs, it would be worth
noting the total K-Ras expression ratios. The ratio of total K-Ras to β-actin in normal
colon epithelial (CCD 841) cell lines was approximately ten times higher than the ratio of
total K-Ras to β-actin in Dukes’ C (HT-29) CRC cell lines (~0.6 vs. 0.05). This might
suggest to us that we did observe a reduction in overall levels of total K-Ras in Dukes’ C
(HT-29) CRC cells hence the resulting decrease in ERK 1/2 activation seen.
Association of the miR-200 family and interaction with the MAPK signaling
pathway is well documented. The majority of knowledge regarding the miR-200 family is
the involvement with epithelial to mesenchymal transition (EMT). The miR-200 family
promotes the epithelial state by suppressing epithelial gene transcriptional repressors,
Zeb1/Zeb2. In one study, overexpression of miR-200c was associated with enhanced
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EGFR and MAPK signaling pathways and lead to suppression of cell invasion in mouse
breast cancer cells.(158) There is also evidence to support the association of miR-200 and
KRAS. In a mutant K-Ras lung adenocarcinoma mouse model, overexpression of miR200a, miR-200b, and miR-429 inhibited tumor growth and metastasis.(159) In addition to
the miR-200 family association with tumor cell invasion, they have been identified to
govern other tumor cell biologic processes, such as proliferation.(160) miR-200c has
been shown to modulate KRAS in breast cancer cell lines. KRAS silencing by miR-200c
lead to reduced proliferation in KRAS wild-type but not KRAS mutated breast cancer
cell lines.(154)
Dysregulation of the miR-200 family has been observed to be both up-regulated
and down-regulated in different types of cancer. The majority of functional studies,
particularly in breast cancer, concentrate on down-regulation of miR-200, suggesting that
miR-200 members prevent tumor progression.(161) Despite this, identification of upregulation of the miR-200 family in cancers, including colorectal cancer, suggests that
miR-200 family members may in fact be promoting progression of certain cancers. In
melanoma cell lines, the levels of miR-200 family members were increased compared to
normal melanocytes, and expression did not suppress tumor invasion.(160) They
identified that up-regulation of miR-200a and miR-200c drives different modes of tumor
cell invasion, either “mesenchymal-type” or “amoeboid-like”. Overall, this group
questioned previous findings of the role of the miR-200 family in suppressing invasion
and metastasis. To support these findings, two other recent studies identified that
overexpression of the miR-200 family promoted cell proliferation in culture, and
metastasis in vivo.(153, 162)
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We believe our findings that a reduction in miR-200 family members leads to a
decrease in MAPK pathway activity and a reduction in cell proliferation in Dukes’ C
(HT-29) CRC cell lines is novel, and suggests that the miR-200 family acts as an
oncogene in CRC. This provides an opportunity to develop new and targeted therapies to
treat colorectal cancer.
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CHAPTER XI
CONCLUDING REMARKS AND DIRECTION OF FUTURE STUDIES

The identification of high expression of the miR-200 family in CRC cell lines
compared to a normal colon epithelial (CCD 841) cell line allowed us to investigate the
role of this family in the progression of CRC. Previous research with the miR-200 family
has focused on EMT of cancer cells where dysregulation is considered to exhibit tumor
suppressive behavior. However; in various cancers increased levels of some individual
members of the miR-200 family contradicts the tumor suppressive role of this miRNA
family. The purpose of this project was to investigate the role of the miR-200 family in
CRC cell lines in order to gain a better understanding regarding the role that this family
plays in colorectal cancer.
Here, we have identified an association between the miR-200 family and the
RASSF2 tumor suppressor, and have investigated their impact on activity within the
MAPK signaling pathway. Overexpression of the miR-200 family in a normal colon
epithelial (CCD841) cell line reduces the expression of RASSF2 protein. RASSF2 binds
to K-Ras. Loss of RASSF2 protein expression increases K-Ras and subsequent activity
with the MAPK signaling pathway, as measured by the downstream pathway protein
ERK 1/2. The resulting outcome is increased cell proliferation, a marker of oncogenesis.
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Conversely, when expression of the miR-200 family in a Dukes’ C (HT-29) CRC cell
line is reduced, RASSF2 protein expression increases and subsequent MAPK signaling
pathway activity decreases. Measurement of cell proliferation confirmed the reduced
growth of these cells. A summary of our results are outlined on page 147.
We have demonstrated the ability of the miR-200 family to transform normal
epithelial cells into cells with more cancer-like behavior, and to transform CRC cells to
cells with a more normal, less malignant behavior. These findings suggest the potential of
the miR-200 family to be developed as a therapeutic target in CRC. Current standard
therapies used in the treatment of CRC include the chemotherapy regime of FOLFOX
(oxaliplatin, 5-FU and leucovorin). This is based on the MOSAIC trial which showed that
in patients with Stage II or III colon cancer, those treated with FOLFOX therapy versus
5-FU and leucovorin had a significantly higher 3-year disease free survival.(163) More
recently, newer agents have been developed to specifically target the gene and protein
changes in cells that cause cancer. Epidermal growth factor receptor (EGFR) protein is
often highly expressed on the surface of cancer cells and is recognized as an important
player in CRC initiation and progression. Anti-EGFR drugs have been developed to
target this protein and reduce cell growth, however; in patients who have a KRAS
mutated CRC, the treatment is ineffective.(164) Similarly, MEK inhibitors have been
developed to target MAPKK enzymes, MEK 1/2, in the MAPK pathway which is often
overactive in some cancers. MEK inhibitors are effective in the treatment of
KRAS/BRAF mutated, but not wild-type CRC.(165)
There are several limitations to this work. Firstly, the use of colorectal cell lines in
research is a cost effective, easy to use method, and provides a pure population of cells
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that are consistent and reproducible, to name but a few advantages. The popularity for the
use of cell lines in research is growing, based upon the number of cell lines available for
use and numerous publications. However; care must be taken when interpreting the
results as serial passage of cell lines can cause phenotypic changes within these cells and
these cells may not always accurately replicate characteristics of the primary cells.
Another problem to note is that of contamination with other cell lines and infection with
mycoplasma. Secondly, transient transfection is most commonly used to investigate the
short-term impact of alterations in gene and protein expression. During transient
transfection, the nucleic acid sequence is not integrated into the cell genome and the
effect on the target gene expression is temporary. Our transfection time was limited to 24
hours to allow for this. Lastly, we investigated the change in miR-200 family expression
in a KRAS wild-type sporadic CRC cell line. KRAS mutations are present in up to 50%
of cases of CRC and occur as point mutations at codons 12 and 13. RASSF2 binds to KRas in the effector binding area on the protein, separate from the area where the
mutations occur, therefore, for the purposes of this study, the KRAS mutation status
should not affect our results. However; for completeness it would be worthwhile to
investigate the role of the miR-200 family in a KRAS mutated CRC cell line for
comparison.
Based on sample size calculations from the screening and validation of
dysregulated miRNAs in colorectal cancer cell lines compared to the normal colon
epithelial cell line (CCD841) a sample size of n=2 was required to achieve a power of
80%. As previously described we chose to perform all experiments with five
experimental replicates to allow for the detection of smaller differences in other
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variables. When measuring RASSF2 mRNA levels, we observed a trend in upregulation
or downregulation, depending on the cell line and miRNA transfection in our replicates,
but this did not reach statistical significance for all the individual miR-200 family
members. It is possible that by increasing the sample size, e.g. n=10, for experiments
where differences in expression were found to be more subtle, we would narrow the
standard deviation and variability, and observe significant differences in cells transfected
with either miR-200 family mimics or antagomirs.
Future considerations include clinical correlation with CRC patient tissue
samples. For example, the use of a tissue microarray to permit simultaneous analysis of
miR-200 family expression and RASSF2 mRNA and protein levels and correlate the
findings with clinical factors would be of interest. In addition, the effects of the miR-200
family on CRC could be measured by using a mouse model. An established miR200c/miR-141 knockout mouse would allow for investigation into the oncogenic features
of the miR-200 family and also allow for testing of miR-200 therapies, such as miRNA
inhibition therapy using miRNA antagonists e.g. siRNA, as a potential treatment in
CRC.
From our colorectal cell line screening we found significant dysregulation of
many miRNAs. While we chose to study the upregulated miR-200 family it is important
to consider the significantly downregulated miRNAs. Comparison of the downregulated
miRNAs in our colorectal cancer cell lines revealed five miRNAs to be common to all,
miR-199a, miR-409, miR-485, miR-541 and miR-654. Each of these miRNAs has been
shown to be involved in cancer pathogenesis.(166-170) Of interest, miR-409 expression
was significantly downregulated in colorectal cancer tissues and negatively regulated
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CRC metastatic capacities, including suppressing cancer cell migration, invasion and
metastasis.(167) miR-199a and miR-541 have previously been regarded as tumor
suppressors and miR-199a has been identified to regulate the tumor suppressor MAP3K.
An area of interest for future study would involve investigation of these downregulated
miRNAs and their associated pathways. It would be interesting to evaluate any targets
common to both the miR-200 family and the downregulated miRNAs with the aim to
enhance miRNA therapy in colorectal cancer in addition to the newer targeted drug
therapies.
The miR-200 family has previously been studied in regards to its regulation of
EMT. EMT is the process where an epithelial cell loses apical/basolateral polarity, severs
intercellular adhesive junctions, degrades basement membrane components and becomes
a migratory mesenchymal cell i.e. enables cells from the primary cancer to travel to
regional nodes or metastatic sites. The miR-200 family plays an important role in
regulating EMT inhibiting the initial step of metastasis by maintaining the epithelial
phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and
ZEB2. Members of the miR-200 family have therefore been believed to play an essential
role in tumor suppression.(161) One of the main pathways involved in this process is the
transforming growth factor beta (TGF-β) signaling pathway. TGF-β signaling pathway is
involved in many cellular processes and suppresses tumor formation by inhibiting cell
growth and promoting apoptosis. In advanced cancers it has been shown to promote
tumor formation by its ability to induce EMT.(171) TGF-β also induces other signaling
pathways and activates the ERK MAPK pathway by allowing the binding of the Grb2Sos1 complex which activates Ras. The interaction of the miR-200 family in both of
147

these signaling pathways is interesting as they play differing roles within each. This
would certainly be an area of interest to study further and improve our understanding of
the cellular processes regulating cancer development.
A recently identified pathway regulated by the miR-200 family is the PI3K/AKT
pathway. This pathway is important in regulating the cell cycle and is directly related to
cell proliferation and apoptosis. Overactivation of this pathway is commonly observed in
cancer. miR-200 activates the PI3K/AKT pathway by targeting FOG2 acting as a PI3K
antagonist. miR-200 was observed to activate AKT through a novel mechanism involving
inactivation of S6K, thus promoting tumor growth.(172)
In conclusion we have identified a novel finding regarding the role of the miR200 family on the tumor suppressor RASSF2 and subsequent activity within the MAPK
signaling pathway in CRC. We have demonstrated the transition of a normal colon
epithelial (CCD 841) cell line towards a “cancer-like” colorectal cell by increasing the
expression of members of the miR-200 family. Conversely, reduction of miR-200 family
expression in a Dukes’ C (HT-29) CRC cell lines reverses this process and the CRC cells
begin to show less “cancer-like” features. This improved understanding of the oncogenic
effects of the miR-200 family may result in a targeted therapy in colorectal cancer.
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APPENDIX: ABBREVIATIONS

A-

miRNA Antagomir Negative Control

AJCC

American Joint Committee on Cancer

AKT

Protein Kinase B (PKB)

APC

Adenomatous Polyposis Coli

AUC

Area Under the Curve

BCA

Bicinchoninic Acid Assay

BRAF

v-Raf Murine Sarcoma Viral Oncogene Homolog B

BSA

Bovine Serum Albumin

CA 19-9

Carbohydrate Antigen 19-9, tumor marker

CA11-19

Colorectal Cancer Tumor marker

CAA

Colorectal Advanced Adenoma

CCD 841

Human Normal Colon Epithelial Cell Line

CEA

Carcinoembryonic Antigen, tumor marker
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CIMP

CpG Island Methylator Phenotype

CIN

Chromosomal Instability

CRC

Colorectal Cancer

DMEM

Dulbecco’s Modified Eagle’s Medium

DMSO

Dimethyl Sulfoxide

DNA

Deoxyribonucleic Acid

dTMP

Deoxythymidine Monophosphate

dUMP

Deoxyuridine Monophosphate

EDTA

Ethylenediaminetetraacetic Acid

EGFR

Epidermal Growth Factor Receptor

ELISA

Enzyme-Linked Immunosorbent Assay

EMEM

Eagle’s Minimum Essential Medium

EMT

Epithelial-Mesenchymal Transition

ERK 1/2

Extracellular Signal-Related Kinase pathway; part of the
MAPK

EtOH

Ethanol

FAP

Familial Adenomatous Polyposis

FBS

Fetal Bovine Serum
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FOBT

Fecal Occult Blood Test

FOG2

Friend of GATA 2

FOLFOX

Chemotherapy Regimen, FOL – Folinic Acid (Leucovorin),
F – Fluorouracil (5-FU), OX - Oxaliplatin

GDP

Guanosine Diphosphate

Grb2-SOS1

Growth Factor Receptor-Bound Protein 2 – Son of
Sevenless homolog 1

GTP

Guanosine Triphosphate

HNPCC

Hereditary Nonpolyposis Colorectal Cancer

HRAS

Harvey Rat Sarcoma Viral Oncogene Homolog

IPA

Ingenuity Pathway Analysis

JNK

c-Jun N-terminal Kinase pathway; part of the MAPK
pathway

KRAS

Kirsten Rat Sarcoma Viral Oncogene Homolog

HT-29

Human Dukes’ C Colorectal Adenocarcinoma Cell Line

M-

miRNA Mimic Negative Control

MAPK

Mitogen-Activated Protein Kinase

MAPKK / MAP2K

Mitogen-Activated Protein Kinase Kinase
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MAPKKK / MAP3K

Mitogen-Activated Protein Kinase Kinase Kinase

MAPK14

Mitogen-Activated Protein Kinase 14, also called p38-α

MEK 1/2

Mitogen-Activated Protein Kinase Kinase; phosphorylates
mitogen-Activated protein kinase

MET

Mesenchymal-Epithelial Transition

miRNA

microRNA: short, single stranded RNA

MLH1

MutL Homolog 1

MMR

Mismatch Repair

MOSAIC

Multicenter International Study of Oxaliplatin/5Fluororuracil/Leucovorin in the Adjuvant Treatment of
Colon Cancer Trial

mRNA

messengerRNA: longer, single stranded RNA; serves as a
template for protein translation

MSI

Microsatellite Instability

MSS

Microsatellite Stable

NRAS

Neuroblastoma Rat Sarcoma Viral Oncogene Homolog

PIK3CA

Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha

PKC

Protein Kinase C
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qRT-PCR

Real-Time Quantitative Reverse Transcription Polymerase
Chain Reaction

RASSF2

Ras Association Domain-Containing Protein 2

RIPA

Radioimmunoprecipitation Assay Buffer

RISC

RNA-Induced Silencing Complex

RNA

Ribonucleic Acid

S6K

Ribosomal Protein (S6) Kinase

SNAIL

Zinc Finger Protein SNAI1

siRNA

Short Interfering RNA; synthetic RNA duplex designed to
specifically target a particular mRNA for degradation

SW1116

Human Dukes’ A Colorectal Adenocarcinoma Cell Line

SW480

Human Dukes’ B Colorectal Adenocarcinoma Cell Line

T84

Human Dukes’ D Colorectal Adenocarcinoma Cell Line

TBS-T

Tris-Buffered Saline and Polysorbate 20

TGF-β

Transforming Growth Factor Beta

TNM

Tumor, Node, Metastasis Classification of Malignant
Tumors

TP53

Tumor Protein p53
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TS

Thymidylate Synthase

Wnt

Wingless-Related Integration Site; Signal transduction
pathway

ZEB 1/2

Zinc Finger E-box Binding Homeobox 1/2

5-FU

5-Fluorouracil
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OTHER PUBLICATIONS DURING TIME OF PhD STUDIES
1.

Carter J, Roberts H, Pan J, et al.,
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma
MicroRNA: Improving Specificity and Sensitivity.
Ann Surg. 2016 Oct;264(4):575-84. doi: 10.1097/SLA.0000000000001873.

2.

Carter J, Pan J, Rai S, Galandiuk S
ROC-ing along: Evaluation and Interpretation of Receiver Operating
Characteristic Curves.
Surgery. 2016 Jun;159(6):1638-45. doi: 10.1016/j.surg.2015.12.029.

3.

Nelson B, Carter J, Eichenberger M, Netz U, Galandiuk S.
Genetic polymorphisms in 5-FU related enzymes predict pathologic response
after neoadjuvant chemoradiation for rectal cancer.
Surgery. 2016 Nov;160(5):1326-1332. doi: 10.1016/j.surg.2016.05.017.

4.

Galbraith N, Walker S, Carter J, Polk HC
Past, present and future of augmentation of monocyte function in the surgical
patient.
Surg Infect (Larchmt). 2016 Oct;17(5):563-9. doi: 10.1089/sur.2016.014.

5.

Bennett J, Carter J, Foy C, Rodd C, Longman R.
Unsupervised use of laparoscopic box trainers in a cohort of UK core surgical
trainees.
Journal of Surgical Simulation, 2016. Accepted In Press.

UNDER REVIEW
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Carter J, Galbraith N, Yang D, Burton J, Walker S, Galandiuk S.
Blood-Based MicroRNA as Biomarkers for the Diagnosis of Colorectal Cancer: A
Systematic Review and Meta-Analysis.
Submitted to: British Journal of Cancer.

2.

Galbraith N, Carter J, Netz U, Yang D, Fry D, McCafferty M, Galandiuk S.
Laparoscopic Lavage in the Management of Perforated Diverticulitis:
A Contemporary Meta-analysis.
Submitted to: JAMA Surgery
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Netz U, Carter J, Eichenberger M, Dryfen G, Pan J, Rai S, Galandiuk S.
Genetic Polymorphisms Predict Anti-TNF Treatment Response in Crohn’s
Disease.
Submitted to: The American Journal of Gastroenterology
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Chapter Malignant Melanoma. Fischer’s Mastery of Surgery 7th Edition. Fischer JE, Bland KI,
Callery MP, eds. Lippincott Williams & Wilkins. Philadelphia. Anticipated 2017
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Chapter 14 Breast Disease. Succeeding in your Medical School Finals: Instant revision notes.
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factors can predict outcome.
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Pre-operative groin discomfort can predict persistent post-operative groin pain despite a
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Herniography influences the management of patients with suspected occult hernia and patient
factors can predict outcome
Hernia 2011; 15 (Supp 1), S78
16. Makawaro T, Phillips J, Gee E, Carter J, Eaton J, Makar A
A study to evaluate the accuracy of magnetic resonance imaging in the staging of prostate cancer
International Journal of Surgery 8 (7); 576

186

PRESENTATIONS
International
1. Carter J, Rice J, Roberts H, Eichenberger MR, Pan J, Kanaan Z, Rai S, Galandiuk S
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA:
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3. Roberts H, McClain M, Rice J, Carter J, Burton J, Galandiuk S
Can Cancer Cell Lines Clarify Molecular Mechanisms of Hereditary Non-Polyposis Colorectal
Cancer?
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4. Carter J, Rice J, McClain M, Farmer R, Galandiuk S
Plasma microRNA to monitor treatment response in patients with colorectal neoplasia
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Are students closing the book on learning?
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Beyond the de facto curriculum – making post exams learning fun
Association for the Study of Medical Education, Brighton, UK
8. Carter J, Bland H, Hannaway N, Fletcher P, Rodd C
Pastoral care in tutorials – Do students get it?
Association for the Study of Medical Education, Brighton, UK
9. Hannaway N, Carter J, Bland H, Fletcher P, Rodd C
How do medical students view their learning opportunities?
Association for the Study of Medical Education, Brighton, UK
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10. Hannaway N, Carter J, Bland H, Rodd C, Fletcher P
Do financial concerns in medical students lead to perceived challenges in learning?
Association for the Study of Medical Education, Brighton, UK
11. Bland H, Hannaway N, Carter J, Fletcher P, Rodd C
Reading anatomy before an imaging tutorial – is there evidence that it aids interpretation of chest
radiographs?
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Does patient gender affect student learning in the clinical setting?
Association for the Study of Medical Education, Brighton, UK
13. Bland H, Nageswaran H, Hannaway N, Carter J, Fletcher P, Rodd C
Teaching and learning professionalism – are teachers and learners in harmony?
Association for the Study of Medical Education, Brighton, UK
Regional/ Local
1. Roberts H, McClain M, Rice J, Carter J, Burton J, Galandiuk S
Can Cancer Cell Lines Clarify Molecular Mechanisms of Hereditary Non-Polyposis Colorectal
Cancer?
Kentucky Chapter American College of Surgeons, Louisville, KY. 1st Prize Winner.
2. Nelson B, Carter J, Eichenberger MR, Netz U, Galandiuk S
Genetic polymorphisms in 5-FU related enzymes predict complete pathologic response following
neoadjuvant chemoradiation for rectal cancer.
Kentucky Chapter American College of Surgeons, Louisville, KY
3. Ward S, Carter J, Robertson C
The use of herniography in the management of patients with suspected occult herniae and how
patient factors can predict outcome.
West Midlands Surgical Society, Birmingham, UK
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International
1. Carter J, Pan J, Rai S, Galandiuk S
ROC-ing along: Evaluation and Interpretation of Receiver Operating Characteristic Curves.
Academic Surgical Congress, Jacksonville, Florida, USA (Manuscript published)
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2. Carter J, States V, Eichenberger MR, Pan J, Rai S, Galandiuk S
Longitudinal Changes in Plasma miRNA in Patients with Benign and Malignant Colorectal
Neoplasia.
Noncoding RNAs and Cancer: Mechanisms to Medicine, AACR, Boston , Massachusetts, USA
3. Carter J, Jenkins M, Coombs N
Pre-operative groin discomfort can predict persistent post-operative pain despite a successful
laparoscopic inguinal hernia repair.
Americas Hernia Society 16th Annual Hernia Repair Congress, Las Vegas, Nevada, USA
4. Carter J, Bland H, Hannaway N, Fletcher P, Rodd C
Video Assisted Learning – Is it always worth it? A randomised control trial
Association for the Study of Medical Education, Brighton, UK
5. Hannaway N, Davies P, Chant H, Bland H, Carter J
Introducing the Observed Structured Student Interactive Clinical Learning Environment
(OSSICLE) – an Interactive Structured Induction Programme for Medical Students
Association for the Study of Medical Education, Brighton, UK
6. Yin J, Carter J, Hunt R, Burd E, El-Abbar M, Price R, Gill J
One UK Breast Unit’s experience of GP 2 week wait referrals to breast care clinic – Are they
appropriate?
ABC1 First Consensus Conference, European School of Oncology, Lisbon, Portugal
7. Carter J, Ward S, Robertson C
The use of herniography in the management of patients with suspected occult hernia and how
patient factors can predict outcome
Americas Hernia Society 14th Annual Hernia Repair Congress, San Francisco, California, USA
(Manuscript published)
National
1. Carter J, Hunt R, Yin J, Burd E, El-Abbar M, Thorne A, Gill J, Price R
NICE Breast Reconstruction Guidelines. Are we good enough?
BASO ~ The Association for Cancer Surgery Scientific Conference, London, UK
2. Hunt R, Ainsworth R, Carter J, Burd E, Price R, Gill J
Patient satisfaction after breast conserving surgery in a District General Hospital: A case for
liposculpture
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3. Makarawo T, Phillips J, Gee E, Carter J, Eaton J, Makar A
A study to evaluate the accuracy of magnetic resonance imaging in the staging of prostate cancer
ASiT, Hull, UK
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1. Makarawo T, Phillips J, Gee E, Carter J, Eaton J, Makar A
A study to evaluate the accuracy of magnetic resonance imaging in the staging of prostate cancer
South Eastern Uro-Oncology Meeting, Cardiff, UK
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RESEARCH EXPERIENCE
As part of my interest in teaching I have initially been involved with research into medical
education, both at an undergraduate and postgraduate level. As part of my year as a clinical
teaching fellow I was involved in several research projects, 4 of them as principle researcher.
Completion of these projects has led to presentations at an international conference. Following
this, I have been involved as joint lead in a postgraduate surgical education research project. My
interest and experience in research has led me to be involved with a large multicentre national
audit as a collaborator.
The principles behind research fascinate me, and as a result I wish to pursue a career in academic
general surgery. My rotations to date have led me to have an interest in colorectal disease, in
particular colorectal cancer. With my long term interest in general surgery I have also been
awarded the Price Institute Surgical Research Fellowship, University of Louisville, Kentucky
USA. I commenced this post in October 2014 where I am studying towards a PhD on the role of
the miRNA-200 family on the tumor suppressor RASSF2 in the development of colorectal
cancer.

AUDITS
J Carter, N Galbraith, S Galandiuk

2015

Very Reliable Ostomy Output Monitoring (VROOM) Training
The purpose of the proposed quality improvement study is to decrease hospital readmission rates
due to dehydration and obstruction following creation of either permanent or temporary
ileostomies in patients with inflammatory bowel disease and rectal cancer.
J Carter, S Williams, J Cook

2013

Intraoperative molecular analysis (OSNA) of total tumour load in sentinel lymph node biopsy
predicting axillary status in breast cancer patients. A retrospective comparison in a UK centre.
J Carter, S Cawthorn

2013

iBRA - A national audit of the practice and outcomes of immediate implant-based breast
reconstruction.
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J Carter, S Narang, S Khadouri S, N Smart

2013

SPARCS National Sepsis Audit
2014

J Carter
Time to flexible sigmoidoscopy
J Carter, R Hunt, J Yin, E Burd, M El-Abbar, R Price, J Gill

2011

NICE Breast Reconstruction Guidelines. Are we good enough?
J Yin, J Carter, R Hunt E Burd, M El-Abbar, R Price, J Gill

2011

One UK breast unit’s experience of GP 2 week wait referrals to breast care clinic – Are they
appropriate?
R Hunt, R Ainsworth, J Carter, E Burd, R Price, J Gill

2010

Patient satisfaction after breast conserving surgery in a District General Hospital: A case for
liposculpture
T Makarawo, J Phillips, E Gee, J Carter, J Eaton, A Makar

2009

A study to evaluate the accuracy of magnetic resonance imaging in the staging of prostate cancer
2009

J Carter
Prescribing in the prevention of osteoporotic fractures
J Carter, J Patel

2008

Documentation of blood tests and chest x-rays by doctors clerking medical patients
J Carter, C Robinson

2007

Radiation protection in the catheterisation laboratory
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POSITIONS OF RESPONSIBILITY / MANAGEMENT
I enjoy taking on managerial responsibilities and projects requiring organisation and leadership
qualities. I am effective at motivating people and achieving set goals. I have taken on roles, both
in my clinical work and outside of medicine, which show my enthusiasm to develop these skills. I
realise that management is an integral part of hospital practice and have so far had the following
experience in management.

The Society for

Candidate Member

Surgery of the

The SSAT is committed to advancing the science

Alimentary Tract

and practice of surgery in the treatment of digestive

2016

disease.
Ad hoc journal

Reviewer of manuscripts submitted to the world’s Aug 2016

reviewer for Diseases of leading peer-reviewed journal in colorectal surgery - Current
the Colon and Rectum

(impact factor 3.739). My specialist interest being
molecular biology and biomarker detection in
colorectal disease.

Restructuring of

Junior representative on restructuring of the August

Emergency Surgery

emergency surgery service in North Bristol NHS 2014

Service

Trust following relocation to Southmead Hospital Supported by Miss A Pullyblank

Commissioning of

Junior lead for commissioning of breast/plastics May-Jun

theatres

theatres in North Bristol NHS Trust. Liaison 2014
amongst multidisciplinary team members and voice
of Consultant body

Clinical Governance

Junior Doctor representative and attendance at 2013-

Group Surgical

monthly CGG meetings

Division member
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2014

Rota coordinator
Breast Surgery

Organisation of the breast surgery rota for junior Apr-Oct

Medical School Course
Planning

During my year as a Clinical Teaching Fellow I 2011-

medical staff at Great Western Hospital

2013

was instrumental in curriculum planning and 2012
development, course design and delivery of
teaching

Organiser of

Organiser for 20 6th form students from local June 2012

“Widening

comprehensive schools interested in applying for

Participation Summer

medicine to attend a week long summer school.

School Programme”

University of

Bristol, Gloucestershire

Royal

Hospital
SIMman training

Lead organiser for recruitment and provision of Jan-Mar
simulation training using SIMman for both 2012
undergraduate medical and nursing students.
Gloucestershire Royal Hospital

MBChB Surgical Skills

Lead organiser of final year MBChB Surgical Sep11-

programme

Skills Programme. Gloucestershire Royal Hospital

Honorary Clinical

Organiser and faculty member of Core Surgical 2011-

Surgical Tutor

Training Days, Severn Deanery

Trauma Simulation

Organiser of multi-disciplinary trauma simulation 2011training

programme.

Gloucestershire

Mar 2012

Current

Royal 2012

Hospital
Honorary Medical

Medical Officer at Point-to-Point Horse Trials. 2009

Officer

Responsible for jockey and crowd safety. Gelligaer
Farmers’ Hunt, Lower Machen
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Mess President

Worcestershire Royal Hospital Mess President

20072008

Ski club captain

University of Bristol Medics ski club captain and 2006-2007
organiser of ski trip for 50 students

Captain of Sports

Captained lacrosse, netball and hockey 1st teams at 2000-2002

Teams

school and university. Player of the year award.

2007

School House Captain

House captain of 100 students

2000-2002
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TEACHING
I have taken an interest in teaching throughout my postgraduate career. My experience so far, as
well as informal student teaching includes:
QUALIFICATIONS
Postgraduate Certificate in Medical Education

2013

Teaching and learning for Health Professionals. University of Bristol
Fellow of the Higher Education Academy

2013

Training the Trainers

2011

Royal College of Surgeons of England
Formal (Full-Time) Teaching Roles
Clinical Teaching

Delivery of medicine and surgery curriculum to 3rd

Fellow

and 5th year medical students from the University

University of Bristol,
Gloucestershire Royal
Hospital

of Bristol. Involvement with evaluation and
restructuring of the undergraduate surgical
education. Provision of clinical teaching, small
group teaching, lecturing, feedback sessions,
pastoral support and examination setting and
marking. In addition to medicine and surgery, I
was also responsible for delivery of professional
behaviour standards, ethics and communication
and equality and diversity teaching. I was also
involved with course development and design for
core surgical skills.
During this post, I managed to maximize the
opportunities for my own clinical learning within
the department by attending regular theatre lists
and clinics.
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2011-2012

Other Teaching Roles
University of Louisville,

Oral examiner of Year 3 Medical Students Surgical

School of Medicine

Rotation

Core Surgical Trainees

Faculty for core surgical skills days. Organisation

Teaching, Severn and

and delivery of teaching to surgical trainees.

2014-Current

2011-2014

Peninsula Deaneries

Introduction to Medical

Invited as speaker and faculty to deliver course on

Education, Course Faculty

introduction to medical education to surgical

2012-2014

trainees.

Honorary Clinical Surgical

Awarded for delivering teaching to core surgical

Tutor

trainees

2011-2013

Severn School of Surgery
Examiner for Final

Regular examiner of long case and OSCE exams

MBChB OSLER & OSCE

for final year medical students

2011-2013

University of Bristol
Examiner, Marker &

Regular examiner, marker and invigilator for 3rd

Invigilator

year medical student examinations

2011-2012

MBChB OSCE & Data
OSCE
University of Bristol
University Medical

Invited to interview 6th form and postgraduate

Admissions Interviewer

students for medical school places

University of Bristol
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2011-2012

Course facilitator for final year medical students

2012

Foundation Year 2

Invited to conduct interview practice for

2012

Interviews

foundation year 2 trainees applying for specialty

Intermediate Life Support
Course Faculty

Faculty

Honorary Clinical Tutor
University of Bristol

training

Awarded for delivering teaching to University of
Bristol Medical Students

Student Selected

Marker of Year 4 MBChB students SSC’s.

Component (SSC) Marker

Required to mark 20 3,000 word reports to count

University of Bristol

Student Mentor

2011-2012

2011

towards overall grade

Medical Student Mentorship Programme

Musgrove Park Hospital
University of Bristol
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2010-2011

OUTSIDE INTERESTS AND ACHIEVEMENTS

USTA League 18 & Over, Louisville, KY

2015-

Women’s State Champions (Lexington, KY)

2016

Mixed Doubles State Champions (Murray, KY)

2016

Women’s Doubles Combo State Champions (Lexington, KY)

2016

Badminton:

Durham County Elite Squad

98-02

Lacrosse:

Polam Hall School for Girls 1st XII Captain

00-02

Netball:

Polam Hall School for Girls 1st VII Captain

00-02

Player of the Year

01-02

University of Bristol 2nd X1

02-04

Polam Hall School for Girls 1st XI Vice-Captain

00-02

University of Bristol Medical School 1st XI Vice-Captain

04-07

Player of the Year

06-07

Tennis:

Hockey:

Football:

Sport has always played a major part in my life. I currently take time to maintain my health by
playing tennis. I have recently represented Kentucky at the Southern Sectional tennis
championships in Mobile, AL, playing against the champions of eight other southern states for
the opportunity to advance to the National finals.
I am a keen traveler and as such I have visited many countries ranging from developed to underdeveloped and have experienced many different cultures and religions.
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